{"transactions":[{"id":691967,"issuer":{"id":5423,"kind":"organization","name":"BlossomHill Therapeutics, Inc."},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":2,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":3,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25047,"kind":"organization","name":"Cormorant Private Healthcare Fund III LP","position":4,"cik":"0001817320","reported_name":"Cormorant Private Healthcare Fund III LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25048,"kind":"organization","name":"Cormorant Private Healthcare Fund V LP","position":5,"cik":"0001969296","reported_name":"Cormorant Private Healthcare Fund V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25049,"kind":"organization","name":"Cormorant Private Healthcare Fund VI, LP","position":6,"cik":"0002098185","reported_name":"Cormorant Private Healthcare Fund VI, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2026-08-10T22:32:08.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":false,"shares":1701541,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F5","text":"Represents (i) 274,912 shares issued upon conversion of shares of Series B Preferred Stock beneficially owned by Master Fund, (ii) 1,052,460 shares issued upon conversion of shares of Series B Preferred Stock beneficially owned by Fund V and (iii) 374,169 shares issued upon conversion of shares of Series B Preferred Stock beneficially owned by Fund VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"), Cormorant Private Healthcare Fund III, LP (\"Fund III\"), Cormorant Private Healthcare Fund V, LP (\"Fund V\") and Cormorant Private Healthcare Fund VI, LP (\"Fund VI\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\"), Cormorant Private Healthcare GP III, LLC (\"GP III\"), Cormorant Private Healthcare GP V, LLC (\"GP V\") and Cormorant Private Healthcare GP VI, LLC\n(\"GP VI\") serve as General Partner of the Master Fund, Fund III, Fund V and Fund VI, respectively."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Bihua Chen serves as manager of Cormorant, GP LLC, GP III, GP V and GP VI. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1701541},"source":{"system":"sec-edgar","filing":"0001231919-26-000852","document":"form4-08102026_100859.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1839970/000123191926000852/form4-08102026_100859.xml","form_type":"4"}},{"id":691966,"issuer":{"id":5423,"kind":"organization","name":"BlossomHill Therapeutics, Inc."},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":2,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":3,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25047,"kind":"organization","name":"Cormorant Private Healthcare Fund III LP","position":4,"cik":"0001817320","reported_name":"Cormorant Private Healthcare Fund III LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25048,"kind":"organization","name":"Cormorant Private Healthcare Fund V LP","position":5,"cik":"0001969296","reported_name":"Cormorant Private Healthcare Fund V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25049,"kind":"organization","name":"Cormorant Private Healthcare Fund VI, LP","position":6,"cik":"0002098185","reported_name":"Cormorant Private Healthcare Fund VI, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2026-08-10T22:32:08.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":false,"shares":1599993,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Represents (i) 1,228,315 shares issued upon conversion of shares of Series A Preferred Stock beneficially owned by Fund III (defined below), and (ii) 371,678 shares issued upon conversion of shares of Series A Preferred Stock beneficially owned by Master Fund (defined below)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"), Cormorant Private Healthcare Fund III, LP (\"Fund III\"), Cormorant Private Healthcare Fund V, LP (\"Fund V\") and Cormorant Private Healthcare Fund VI, LP (\"Fund VI\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\"), Cormorant Private Healthcare GP III, LLC (\"GP III\"), Cormorant Private Healthcare GP V, LLC (\"GP V\") and Cormorant Private Healthcare GP VI, LLC\n(\"GP VI\") serve as General Partner of the Master Fund, Fund III, Fund V and Fund VI, respectively."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Bihua Chen serves as manager of Cormorant, GP LLC, GP III, GP V and GP VI. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1599993},"source":{"system":"sec-edgar","filing":"0001231919-26-000852","document":"form4-08102026_100859.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1839970/000123191926000852/form4-08102026_100859.xml","form_type":"4"}},{"id":691965,"issuer":{"id":5423,"kind":"organization","name":"BlossomHill Therapeutics, Inc."},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":2,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":3,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25047,"kind":"organization","name":"Cormorant Private Healthcare Fund III LP","position":4,"cik":"0001817320","reported_name":"Cormorant Private Healthcare Fund III LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25048,"kind":"organization","name":"Cormorant Private Healthcare Fund V LP","position":5,"cik":"0001969296","reported_name":"Cormorant Private Healthcare Fund V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25049,"kind":"organization","name":"Cormorant Private Healthcare Fund VI, LP","position":6,"cik":"0002098185","reported_name":"Cormorant Private Healthcare Fund VI, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2026-08-10T22:32:08.000Z","date":"2026-08-06","kind":"grant","planned":false,"acquired":true,"shares":23904,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"1/36th of the shares subject to the option shall vest in equal monthly installments over a three year period following August 6, 2026."}],"balance_after":23904,"derivative":{"exercise_price":16,"expiration_date":"2036-08-05","underlying":"Common Stock","underlying_shares":23904},"source":{"system":"sec-edgar","filing":"0001231919-26-000852","document":"form4-08102026_100859.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1839970/000123191926000852/form4-08102026_100859.xml","form_type":"4"}},{"id":691964,"issuer":{"id":5423,"kind":"organization","name":"BlossomHill Therapeutics, Inc."},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":2,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":3,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25047,"kind":"organization","name":"Cormorant Private Healthcare Fund III LP","position":4,"cik":"0001817320","reported_name":"Cormorant Private Healthcare Fund III LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25048,"kind":"organization","name":"Cormorant Private Healthcare Fund V LP","position":5,"cik":"0001969296","reported_name":"Cormorant Private Healthcare Fund V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25049,"kind":"organization","name":"Cormorant Private Healthcare Fund VI, LP","position":6,"cik":"0002098185","reported_name":"Cormorant Private Healthcare Fund VI, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-10T22:32:08.000Z","date":"2026-08-10","kind":"purchase","planned":false,"acquired":true,"shares":312500,"price":16,"value":5000000.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F7","text":"The shares purchased are beneficially owned by Master Fund."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F8","text":"Represents an aggregate of (i) 959,090 shares beneficially owned by Master Fund, (ii) 1,228,315 shares beneficially owned by Fund III, (iii) 1,052,460 shares beneficially owned by Fund V, and (vi) 374,169 beneficially owned by Fund VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"), Cormorant Private Healthcare Fund III, LP (\"Fund III\"), Cormorant Private Healthcare Fund V, LP (\"Fund V\") and Cormorant Private Healthcare Fund VI, LP (\"Fund VI\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\"), Cormorant Private Healthcare GP III, LLC (\"GP III\"), Cormorant Private Healthcare GP V, LLC (\"GP V\") and Cormorant Private Healthcare GP VI, LLC\n(\"GP VI\") serve as General Partner of the Master Fund, Fund III, Fund V and Fund VI, respectively."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Bihua Chen serves as manager of Cormorant, GP LLC, GP III, GP V and GP VI. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."}],"balance_after":3614034,"source":{"system":"sec-edgar","filing":"0001231919-26-000852","document":"form4-08102026_100859.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1839970/000123191926000852/form4-08102026_100859.xml","form_type":"4"}},{"id":691963,"issuer":{"id":5423,"kind":"organization","name":"BlossomHill Therapeutics, Inc."},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":2,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":3,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25047,"kind":"organization","name":"Cormorant Private Healthcare Fund III LP","position":4,"cik":"0001817320","reported_name":"Cormorant Private Healthcare Fund III LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25048,"kind":"organization","name":"Cormorant Private Healthcare Fund V LP","position":5,"cik":"0001969296","reported_name":"Cormorant Private Healthcare Fund V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25049,"kind":"organization","name":"Cormorant Private Healthcare Fund VI, LP","position":6,"cik":"0002098185","reported_name":"Cormorant Private Healthcare Fund VI, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-10T22:32:08.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":true,"shares":1701541,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Represents (i) 274,912 shares issued upon conversion of shares of Series B Preferred Stock beneficially owned by Master Fund, (ii) 1,052,460 shares issued upon conversion of shares of Series B Preferred Stock beneficially owned by Fund V and (iii) 374,169 shares issued upon conversion of shares of Series B Preferred Stock beneficially owned by Fund VI."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"Represents an aggregate of (i) 646,590 shares beneficially owned by Master Fund, (ii) 1,228,315 shares beneficially owned by Fund III, (iii) 1,052,460 shares beneficially owned by Fund V, and (vi) 374,169 beneficially owned by Fund VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"), Cormorant Private Healthcare Fund III, LP (\"Fund III\"), Cormorant Private Healthcare Fund V, LP (\"Fund V\") and Cormorant Private Healthcare Fund VI, LP (\"Fund VI\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\"), Cormorant Private Healthcare GP III, LLC (\"GP III\"), Cormorant Private Healthcare GP V, LLC (\"GP V\") and Cormorant Private Healthcare GP VI, LLC\n(\"GP VI\") serve as General Partner of the Master Fund, Fund III, Fund V and Fund VI, respectively."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Bihua Chen serves as manager of Cormorant, GP LLC, GP III, GP V and GP VI. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."}],"balance_after":3301534,"source":{"system":"sec-edgar","filing":"0001231919-26-000852","document":"form4-08102026_100859.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1839970/000123191926000852/form4-08102026_100859.xml","form_type":"4"}},{"id":691962,"issuer":{"id":5423,"kind":"organization","name":"BlossomHill Therapeutics, Inc."},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":2,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":3,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25047,"kind":"organization","name":"Cormorant Private Healthcare Fund III LP","position":4,"cik":"0001817320","reported_name":"Cormorant Private Healthcare Fund III LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25048,"kind":"organization","name":"Cormorant Private Healthcare Fund V LP","position":5,"cik":"0001969296","reported_name":"Cormorant Private Healthcare Fund V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25049,"kind":"organization","name":"Cormorant Private Healthcare Fund VI, LP","position":6,"cik":"0002098185","reported_name":"Cormorant Private Healthcare Fund VI, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-10T22:32:08.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":true,"shares":1599993,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents (i) 1,228,315 shares issued upon conversion of shares of Series A Preferred Stock beneficially owned by Fund III (defined below), and (ii) 371,678 shares issued upon conversion of shares of Series A Preferred Stock beneficially owned by Master Fund (defined below)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Represents (i) 1,228,315 shares issued upon conversion of shares of Series A Preferred Stock beneficially owned by Fund III (defined below), and (ii) 371,678 shares issued upon conversion of shares of Series A Preferred Stock beneficially owned by Master Fund (defined below)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"), Cormorant Private Healthcare Fund III, LP (\"Fund III\"), Cormorant Private Healthcare Fund V, LP (\"Fund V\") and Cormorant Private Healthcare Fund VI, LP (\"Fund VI\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\"), Cormorant Private Healthcare GP III, LLC (\"GP III\"), Cormorant Private Healthcare GP V, LLC (\"GP V\") and Cormorant Private Healthcare GP VI, LLC\n(\"GP VI\") serve as General Partner of the Master Fund, Fund III, Fund V and Fund VI, respectively."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Bihua Chen serves as manager of Cormorant, GP LLC, GP III, GP V and GP VI. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."}],"balance_after":1599993,"source":{"system":"sec-edgar","filing":"0001231919-26-000852","document":"form4-08102026_100859.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1839970/000123191926000852/form4-08102026_100859.xml","form_type":"4"}},{"id":715543,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-07-06T20:34:53.000Z","date":"2026-07-01","kind":"other","planned":false,"acquired":true,"shares":130865,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Via Master Fund"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Cormorant Global Healthcare Master Fund, LP (\"Master Fund\"), which is an investment vehicle managed by CAM, is a member of the Sponsor and received such shares in a pro rata distribution by the Sponsor for no consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"CAM serves as the investment manager to Fund III, Cormorant Private Healthcare Fund IV, LP (\"Fund IV\"), Fund V, and Master Fund (collectively, the \"Cormorant Funds\"). Cormorant Private Healthcare GP III, LLC (\"GP III\") is the general partner of Fund III; Cormorant Private Healthcare GP IV, LLC (\"GP IV\") is the general partner of Fund IV; Cormorant Private Healthcare GP V, LLC (\"GP V\") is the general partner of Fund V; and Cormorant Global Healthcare GP, LLC (\"Global GP\") is the general partner of the Master Fund. Bihua Chen serves as the managing member of GP III, GP IV, GP V, and Global GP, and as the general partner of CAM. Accordingly, Ms. Chen has voting and investment discretion with respect to the shares held by each of the Cormorant Funds and CAM. Ms. Chen disclaims any beneficial ownership of the securities held by each of the Cormorant Funds other than to the extent of any pecuniary interest she may have therein, directly or indirectly."}],"balance_after":6083221,"source":{"system":"sec-edgar","filing":"0001213900-26-075538","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000121390026075538/ownership.xml","form_type":"4"}},{"id":715542,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-07-06T20:34:53.000Z","date":"2026-07-01","kind":"other","planned":false,"acquired":true,"shares":1704862,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Via Fund V"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Cormorant Private Healthcare Fund V, LP (\"Fund V\"), which is an investment vehicle managed by CAM, is a member of the Sponsor and received such shares in a pro rata distribution by the Sponsor for no consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"CAM serves as the investment manager to Fund III, Cormorant Private Healthcare Fund IV, LP (\"Fund IV\"), Fund V, and Master Fund (collectively, the \"Cormorant Funds\"). Cormorant Private Healthcare GP III, LLC (\"GP III\") is the general partner of Fund III; Cormorant Private Healthcare GP IV, LLC (\"GP IV\") is the general partner of Fund IV; Cormorant Private Healthcare GP V, LLC (\"GP V\") is the general partner of Fund V; and Cormorant Global Healthcare GP, LLC (\"Global GP\") is the general partner of the Master Fund. Bihua Chen serves as the managing member of GP III, GP IV, GP V, and Global GP, and as the general partner of CAM. Accordingly, Ms. Chen has voting and investment discretion with respect to the shares held by each of the Cormorant Funds and CAM. Ms. Chen disclaims any beneficial ownership of the securities held by each of the Cormorant Funds other than to the extent of any pecuniary interest she may have therein, directly or indirectly."}],"balance_after":5010332,"source":{"system":"sec-edgar","filing":"0001213900-26-075538","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000121390026075538/ownership.xml","form_type":"4"}},{"id":715541,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-07-06T20:34:53.000Z","date":"2026-07-01","kind":"other","planned":false,"acquired":true,"shares":2692459,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Via Fund III"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Cormorant Private Healthcare Fund III, LP (\"Fund III\"), which is an investment vehicle managed by Cormorant Asset Management, LP (\"CAM\"), is a member of the Sponsor and received such shares in a pro rata distribution by the Sponsor for no consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"CAM serves as the investment manager to Fund III, Cormorant Private Healthcare Fund IV, LP (\"Fund IV\"), Fund V, and Master Fund (collectively, the \"Cormorant Funds\"). Cormorant Private Healthcare GP III, LLC (\"GP III\") is the general partner of Fund III; Cormorant Private Healthcare GP IV, LLC (\"GP IV\") is the general partner of Fund IV; Cormorant Private Healthcare GP V, LLC (\"GP V\") is the general partner of Fund V; and Cormorant Global Healthcare GP, LLC (\"Global GP\") is the general partner of the Master Fund. Bihua Chen serves as the managing member of GP III, GP IV, GP V, and Global GP, and as the general partner of CAM. Accordingly, Ms. Chen has voting and investment discretion with respect to the shares held by each of the Cormorant Funds and CAM. Ms. Chen disclaims any beneficial ownership of the securities held by each of the Cormorant Funds other than to the extent of any pecuniary interest she may have therein, directly or indirectly."}],"balance_after":4879995,"source":{"system":"sec-edgar","filing":"0001213900-26-075538","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000121390026075538/ownership.xml","form_type":"4"}},{"id":715540,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-07-06T20:34:53.000Z","date":"2026-07-01","kind":"other","planned":false,"acquired":false,"shares":4528186,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Via Helix Holdings II LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a pro rata distribution to the members of Helix Holdings II LLC (the \"Sponsor\") for no consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Sponsor is the record holder of the securities reported herein. Fund III, Fund V, and Master Fund are the members of Sponsor. Bihua Chen is the manager of Sponsor and has voting and investment discretion with respect to the shares held of record by Sponsor. Each of Fund III, Fund V, Master Fund and Ms. Chen disclaims any beneficial ownership of the securities held by Sponsor other than to the extent of any pecuniary interest she or it may have therein, directly or indirectly."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001213900-26-075538","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000121390026075538/ownership.xml","form_type":"4"}},{"id":732284,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-18T20:55:36.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":31675,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the stock option vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting of Stockholders of the Issuer following the date of grant, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date."}],"balance_after":31675,"derivative":{"exercise_price":7.73,"expiration_date":"2036-06-15","underlying":"Common Stock","underlying_shares":31675},"source":{"system":"sec-edgar","filing":"0001193125-26-276041","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000119312526276041/ownership.xml","form_type":"4"}},{"id":797438,"issuer":{"id":5231,"kind":"organization","name":"BRIGHT MINDS BIOSCIENCES INC."},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":25044,"kind":"person","name":"Chen Bihua","position":2,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":3,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Shares","published_at":"2026-04-30T20:07:58.000Z","date":"2026-04-28","kind":"sale","planned":false,"acquired":false,"shares":109331,"price":89.5,"value":9785124.5,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\") serves as the general partner of the Master Fund. Bihua Chen serves as the managing member of Cormorant, GP LLC and the Master Fund. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."}],"balance_after":950000,"source":{"system":"sec-edgar","filing":"0000929638-26-001708","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1827401/000092963826001708/form4.xml","form_type":"4"}},{"id":928757,"issuer":{"id":6010,"kind":"organization","name":"Helix Acquisition Corp. III"},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairperson and CEO"}},{"id":68573,"kind":"organization","name":"Helix Holdings III LLC","position":2,"cik":"0002105798","reported_name":"Helix Holdings III LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Class B Ordinary Shares","published_at":"2026-01-29T01:36:50.000Z","date":"2026-01-22","kind":"other","planned":false,"acquired":true,"shares":718750,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"As described in the Registration Statement, under the heading \"Description of Securities--Founder Shares and Private Placement Shares\", the terms of the Class B ordinary shares, par value $0.0001 per share, provided at issuance that they would automatically convert into Class A ordinary shares, par value $0.0001 per share, concurrently with or immediately following the consummation of the Issuer's initial business combination or earlier at the option of the holder on a one-for-one basis, subject to adjustment for share sub-divisions, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"As described in the Registration Statement, under the heading \"Description of Securities--Founder Shares and Private Placement Shares\", the terms of the Class B ordinary shares, par value $0.0001 per share, provided at issuance that they would automatically convert into Class A ordinary shares, par value $0.0001 per share, concurrently with or immediately following the consummation of the Issuer's initial business combination or earlier at the option of the holder on a one-for-one basis, subject to adjustment for share sub-divisions, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date."},{"field":"kind","element":"transactionCoding","label":"F5","text":"On January 22, 2026, the Issuer effected a share capitalization with respect to the Class B ordinary shares, resulting in the issue and allotment of 718,750 Class B ordinary shares to Helix Holdings III LLC."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"As described in the Registration Statement, under the heading \"Description of Securities--Founder Shares and Private Placement Shares\", the terms of the Class B ordinary shares, par value $0.0001 per share, provided at issuance that they would automatically convert into Class A ordinary shares, par value $0.0001 per share, concurrently with or immediately following the consummation of the Issuer's initial business combination or earlier at the option of the holder on a one-for-one basis, subject to adjustment for share sub-divisions, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On January 22, 2026, the Issuer effected a share capitalization with respect to the Class B ordinary shares, resulting in the issue and allotment of 718,750 Class B ordinary shares to Helix Holdings III LLC."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"As described in the Registration Statement, under the heading \"Description of Securities--Founder Shares and Private Placement Shares\", the terms of the Class B ordinary shares, par value $0.0001 per share, provided at issuance that they would automatically convert into Class A ordinary shares, par value $0.0001 per share, concurrently with or immediately following the consummation of the Issuer's initial business combination or earlier at the option of the holder on a one-for-one basis, subject to adjustment for share sub-divisions, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"As described in the Registration Statement, under the heading \"Description of Securities--Founder Shares and Private Placement Shares\", the terms of the Class B ordinary shares, par value $0.0001 per share, provided at issuance that they would automatically convert into Class A ordinary shares, par value $0.0001 per share, concurrently with or immediately following the consummation of the Issuer's initial business combination or earlier at the option of the holder on a one-for-one basis, subject to adjustment for share sub-divisions, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Helix Holdings III LLC is the record holder of the securities reported herein. Cormorant Private Healthcare Fund VI, LP (\"Cormorant Fund VI\") and Cormorant Global Healthcare Master Fund, LP, together own 100% of the membership interests in Helix Holdings III LLC. Bihua Chen is the managing member of each of Cormorant Fund VI and Cormorant Global Healthcare Master Fund, LP and has voting and investment discretion with respect to the ordinary shares held of record by Helix Holdings III LLC. Bihua Chen disclaims any beneficial ownership of the securities held by Helix Holdings III LLC other than to the extent of any pecuniary interest she may have therein, directly or indirectly."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Helix Holdings III LLC is the record holder of the securities reported herein. Cormorant Private Healthcare Fund VI, LP (\"Cormorant Fund VI\") and Cormorant Global Healthcare Master Fund, LP, together own 100% of the membership interests in Helix Holdings III LLC. Bihua Chen is the managing member of each of Cormorant Fund VI and Cormorant Global Healthcare Master Fund, LP and has voting and investment discretion with respect to the ordinary shares held of record by Helix Holdings III LLC. Bihua Chen disclaims any beneficial ownership of the securities held by Helix Holdings III LLC other than to the extent of any pecuniary interest she may have therein, directly or indirectly."}],"balance_after":4252500,"derivative":{"underlying":"Class A Ordinary Shares","underlying_shares":718750},"source":{"system":"sec-edgar","filing":"0001213900-26-009021","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1599214/000121390026009021/ownership.xml","form_type":"4/A","original_submission_date":"2026-01-26"}},{"id":928756,"issuer":{"id":6010,"kind":"organization","name":"Helix Acquisition Corp. III"},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairperson and CEO"}},{"id":68573,"kind":"organization","name":"Helix Holdings III LLC","position":2,"cik":"0002105798","reported_name":"Helix Holdings III LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Class A Ordinary Shares","published_at":"2026-01-29T01:36:50.000Z","date":"2026-01-26","kind":"purchase","planned":false,"acquired":true,"shares":800000,"price":10,"value":8000000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"This form amends a Form 4 previously filed for the Reporting Person on January 26, 2026 to correct the number of shares that should have been reported on such date, which now includes shares purchased by Cormorant Global Healthcare Master Fund, LP in the Issuer's initial public offering, as described in further detail in the Issuer's registration statement on Form S-1 (File No. 333-291933) (\"Registration Statement\")."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Cormorant Global Healthcare Master Fund, LP is the record holder of such securities. Ms. Chen is the managing member of Cormorant Global Healthcare Master Fund, LP and has voting and investment discretion with respect to the ordinary shares of record held thereby. Ms. Chen disclaims any beneficial ownership of the securities held by Cormorant Global Healthcare Master Fund, LP other than to the extent of any pecuniary interest she may have therein, directly or indirectly."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This form amends a Form 4 previously filed for the Reporting Person on January 26, 2026 to correct the number of shares that should have been reported on such date, which now includes shares purchased by Cormorant Global Healthcare Master Fund, LP in the Issuer's initial public offering, as described in further detail in the Issuer's registration statement on Form S-1 (File No. 333-291933) (\"Registration Statement\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cormorant Global Healthcare Master Fund, LP is the record holder of such securities. Ms. Chen is the managing member of Cormorant Global Healthcare Master Fund, LP and has voting and investment discretion with respect to the ordinary shares of record held thereby. Ms. Chen disclaims any beneficial ownership of the securities held by Cormorant Global Healthcare Master Fund, LP other than to the extent of any pecuniary interest she may have therein, directly or indirectly."}],"balance_after":800000,"source":{"system":"sec-edgar","filing":"0001213900-26-009021","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1599214/000121390026009021/ownership.xml","form_type":"4/A","original_submission_date":"2026-01-26"}},{"id":928755,"issuer":{"id":6010,"kind":"organization","name":"Helix Acquisition Corp. III"},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairperson and CEO"}},{"id":68573,"kind":"organization","name":"Helix Holdings III LLC","position":2,"cik":"0002105798","reported_name":"Helix Holdings III LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Class A Ordinary Shares","published_at":"2026-01-29T01:36:50.000Z","date":"2026-01-26","kind":"grant","planned":false,"acquired":true,"shares":497500,"price":10,"value":4975000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Helix Holdings III LLC is the record holder of the securities reported herein. Cormorant Private Healthcare Fund VI, LP (\"Cormorant Fund VI\") and Cormorant Global Healthcare Master Fund, LP, together own 100% of the membership interests in Helix Holdings III LLC. Bihua Chen is the managing member of each of Cormorant Fund VI and Cormorant Global Healthcare Master Fund, LP and has voting and investment discretion with respect to the ordinary shares held of record by Helix Holdings III LLC. Bihua Chen disclaims any beneficial ownership of the securities held by Helix Holdings III LLC other than to the extent of any pecuniary interest she may have therein, directly or indirectly."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Helix Holdings III LLC is the record holder of the securities reported herein. Cormorant Private Healthcare Fund VI, LP (\"Cormorant Fund VI\") and Cormorant Global Healthcare Master Fund, LP, together own 100% of the membership interests in Helix Holdings III LLC. Bihua Chen is the managing member of each of Cormorant Fund VI and Cormorant Global Healthcare Master Fund, LP and has voting and investment discretion with respect to the ordinary shares held of record by Helix Holdings III LLC. Bihua Chen disclaims any beneficial ownership of the securities held by Helix Holdings III LLC other than to the extent of any pecuniary interest she may have therein, directly or indirectly."}],"balance_after":497500,"source":{"system":"sec-edgar","filing":"0001213900-26-009021","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1599214/000121390026009021/ownership.xml","form_type":"4/A","original_submission_date":"2026-01-26"}},{"id":931025,"issuer":{"id":6010,"kind":"organization","name":"Helix Acquisition Corp. III"},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairperson and CEO"}},{"id":68573,"kind":"organization","name":"Helix Holdings III LLC","position":2,"cik":"0002105798","reported_name":"Helix Holdings III LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Class B Ordinary Shares","published_at":"2026-01-26T22:02:48.000Z","date":"2026-01-22","kind":"other","planned":false,"acquired":true,"shares":718750,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"As described in the Issuer's registration statement on Form S-1 (File No. 333-291933) (\"Registration Statement\"), under the heading \"Description of Securities--Founder Shares and Private Placement Shares\", the terms of the Class B ordinary shares, par value $0.0001 per share, provided at issuance that they would automatically convert into Class A ordinary shares, par value $0.0001 per share, concurrently with or immediately following the consummation of the Issuer's initial business combination or earlier at the option of the holder on a one-for-one basis, subject to adjustment for share sub-divisions, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"As described in the Issuer's registration statement on Form S-1 (File No. 333-291933) (\"Registration Statement\"), under the heading \"Description of Securities--Founder Shares and Private Placement Shares\", the terms of the Class B ordinary shares, par value $0.0001 per share, provided at issuance that they would automatically convert into Class A ordinary shares, par value $0.0001 per share, concurrently with or immediately following the consummation of the Issuer's initial business combination or earlier at the option of the holder on a one-for-one basis, subject to adjustment for share sub-divisions, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date."},{"field":"kind","element":"transactionCoding","label":"F3","text":"On January 22, 2026, the Issuer effected a share capitalization with respect to the Class B ordinary shares, resulting in the issue and allotment of 718,750 Class B ordinary shares to Helix Holdings III LLC."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"As described in the Issuer's registration statement on Form S-1 (File No. 333-291933) (\"Registration Statement\"), under the heading \"Description of Securities--Founder Shares and Private Placement Shares\", the terms of the Class B ordinary shares, par value $0.0001 per share, provided at issuance that they would automatically convert into Class A ordinary shares, par value $0.0001 per share, concurrently with or immediately following the consummation of the Issuer's initial business combination or earlier at the option of the holder on a one-for-one basis, subject to adjustment for share sub-divisions, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On January 22, 2026, the Issuer effected a share capitalization with respect to the Class B ordinary shares, resulting in the issue and allotment of 718,750 Class B ordinary shares to Helix Holdings III LLC."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"As described in the Issuer's registration statement on Form S-1 (File No. 333-291933) (\"Registration Statement\"), under the heading \"Description of Securities--Founder Shares and Private Placement Shares\", the terms of the Class B ordinary shares, par value $0.0001 per share, provided at issuance that they would automatically convert into Class A ordinary shares, par value $0.0001 per share, concurrently with or immediately following the consummation of the Issuer's initial business combination or earlier at the option of the holder on a one-for-one basis, subject to adjustment for share sub-divisions, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"As described in the Issuer's registration statement on Form S-1 (File No. 333-291933) (\"Registration Statement\"), under the heading \"Description of Securities--Founder Shares and Private Placement Shares\", the terms of the Class B ordinary shares, par value $0.0001 per share, provided at issuance that they would automatically convert into Class A ordinary shares, par value $0.0001 per share, concurrently with or immediately following the consummation of the Issuer's initial business combination or earlier at the option of the holder on a one-for-one basis, subject to adjustment for share sub-divisions, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Helix Holdings III LLC is the record holder of the securities reported herein. Cormorant Private Healthcare Fund VI, LP (\"Cormorant Fund VI\") and Cormorant Global Healthcare Master Fund (\"Cormorant Master Fund\"), LP, together own 100% of the membership interests in Helix Holdings III LLC. Bihua Chen is the managing member of each of Cormorant Fund VI and Cormorant Master Fund and has voting and investment discretion with respect to the ordinary shares held of record by Helix Holdings III LLC. Bihua Chen disclaims any beneficial ownership of the securities held by Helix Holdings III LLC other than to the extent of any pecuniary interest she may have therein, directly or indirectly."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Helix Holdings III LLC is the record holder of the securities reported herein. Cormorant Private Healthcare Fund VI, LP (\"Cormorant Fund VI\") and Cormorant Global Healthcare Master Fund (\"Cormorant Master Fund\"), LP, together own 100% of the membership interests in Helix Holdings III LLC. Bihua Chen is the managing member of each of Cormorant Fund VI and Cormorant Master Fund and has voting and investment discretion with respect to the ordinary shares held of record by Helix Holdings III LLC. Bihua Chen disclaims any beneficial ownership of the securities held by Helix Holdings III LLC other than to the extent of any pecuniary interest she may have therein, directly or indirectly."}],"balance_after":4252500,"derivative":{"underlying":"Class A Ordinary Shares","underlying_shares":718750},"source":{"system":"sec-edgar","filing":"0001213900-26-007772","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1599214/000121390026007772/ownership.xml","form_type":"4"}},{"id":931024,"issuer":{"id":6010,"kind":"organization","name":"Helix Acquisition Corp. III"},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairperson and CEO"}},{"id":68573,"kind":"organization","name":"Helix Holdings III LLC","position":2,"cik":"0002105798","reported_name":"Helix Holdings III LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Class A Ordinary Shares","published_at":"2026-01-26T22:02:48.000Z","date":"2026-01-26","kind":"grant","planned":false,"acquired":true,"shares":497500,"price":10,"value":4975000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Helix Holdings III LLC is the record holder of the securities reported herein. Cormorant Private Healthcare Fund VI, LP (\"Cormorant Fund VI\") and Cormorant Global Healthcare Master Fund (\"Cormorant Master Fund\"), LP, together own 100% of the membership interests in Helix Holdings III LLC. Bihua Chen is the managing member of each of Cormorant Fund VI and Cormorant Master Fund and has voting and investment discretion with respect to the ordinary shares held of record by Helix Holdings III LLC. Bihua Chen disclaims any beneficial ownership of the securities held by Helix Holdings III LLC other than to the extent of any pecuniary interest she may have therein, directly or indirectly."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Helix Holdings III LLC is the record holder of the securities reported herein. Cormorant Private Healthcare Fund VI, LP (\"Cormorant Fund VI\") and Cormorant Global Healthcare Master Fund (\"Cormorant Master Fund\"), LP, together own 100% of the membership interests in Helix Holdings III LLC. Bihua Chen is the managing member of each of Cormorant Fund VI and Cormorant Master Fund and has voting and investment discretion with respect to the ordinary shares held of record by Helix Holdings III LLC. Bihua Chen disclaims any beneficial ownership of the securities held by Helix Holdings III LLC other than to the extent of any pecuniary interest she may have therein, directly or indirectly."}],"balance_after":497500,"source":{"system":"sec-edgar","filing":"0001213900-26-007772","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1599214/000121390026007772/ownership.xml","form_type":"4"}},{"id":968846,"issuer":{"id":6261,"kind":"organization","name":"Corbus Pharmaceuticals Holdings, Inc.","symbol":"CRBP"},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"ten_percent_owner":true}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":2,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"ten_percent_owner":true}},{"id":25044,"kind":"person","name":"Chen Bihua","position":3,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2025-12-15T21:18:06.000Z","date":"2025-12-11","kind":"sale","planned":false,"acquired":false,"shares":30029,"price":11.456,"value":344012.224,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price represents the weighted average sale price of Common Stock (the \"shares\") sold in a series of open market transactions on the transaction date at prices ranging from $11.20 to $12.15 per share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of the shares reported herein were sold by the Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\") serves as the general partner of the Master Fund. Bihua Chen serves as the managing member of Cormorant, GP LLC and the Master Fund. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."}],"balance_after":2344971,"source":{"system":"sec-edgar","filing":"0000929638-25-004597","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583977/000092963825004597/form4.xml","form_type":"4"}},{"id":977411,"issuer":{"id":5702,"kind":"organization","name":"EyePoint, Inc."},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":2,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":25044,"kind":"person","name":"Chen Bihua","position":3,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock","published_at":"2025-12-08T21:03:52.000Z","date":"2025-12-04","kind":"sale","planned":false,"acquired":false,"shares":60000,"price":15.704,"value":942240.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price represents the weighted average sale price of Common Stock (the \"shares\") sold in a series of open market transactions on the transaction date at prices ranging from $15.70 to $15.97 per share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of the shares reported herein were sold by the Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\") serves as the general partner of the Master Fund. Bihua Chen serves as the managing member of Cormorant, GP LLC and the Master Fund. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."}],"balance_after":8265000,"source":{"system":"sec-edgar","filing":"0000929638-25-004521","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314102/000092963825004521/form4.xml","form_type":"4"}},{"id":1029424,"issuer":{"id":4785,"kind":"organization","name":"MoonLake Immunotherapeutics"},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":2,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":3,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":74740,"kind":"organization","name":"Cormorant Private Healthcare Fund II, LP","position":4,"cik":"0001747677","reported_name":"Cormorant Private Healthcare Fund II, LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":25047,"kind":"organization","name":"Cormorant Private Healthcare Fund III LP","position":5,"cik":"0001817320","reported_name":"Cormorant Private Healthcare Fund III LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":74741,"kind":"organization","name":"Cormorant Private Healthcare Fund IV LP","position":6,"cik":"0001871297","reported_name":"Cormorant Private Healthcare Fund IV LP","relationship":{"other":true,"other_text":"Former 10% Owner"}}],"security":"Class A Ordinary Shares","published_at":"2025-10-01T21:22:38.000Z","date":"2025-09-30","kind":"sale","planned":false,"acquired":false,"shares":5827,"price":6.96,"value":40555.92,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F11","text":"Represents the weighted average sale price of Class A Ordinary Shares (\"Shares\") sold in a series of open market transactions on the transaction date at prices ranging from $6.94 to $6.99 per Share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of Shares sold at each price. All of these Shares were sold by the Account."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Information reported herein relates to Shares owned by Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"), Cormorant Private Healthcare Fund II, LP (\"Fund II\"), Cormorant Private Healthcare Fund III, LP (\"Fund III\"), Cormorant Private Healthcare Fund IV, LP (\"Fund IV\") and a managed account (the \"Account\" and together with the Master Fund, Fund II, Fund III and Fund IV, the \"Funds\")). Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of the Funds. Cormorant Global Healthcare GP, LLC (\"GP LLC\"), Cormorant Private Healthcare GP II, LLC (\"GP II\"), Cormorant Private Healthcare GP III, LLC (\"GP III\") and Cormorant Private Healthcare GP IV, LLC (\"GP IV\") serve as General Partner of the Master Fund, Fund II, Fund III and Fund IV, respectively. Bihua Chen serves as manager of Cormorant, GP LLC, GP II, GP III and GP IV."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Persons disclaims beneficial ownership of the Shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such ordinary shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F12","text":"Represents (i) 638,740 Shares beneficially owned by the Master Fund, (ii) 424,466 Shares beneficially owned by Fund II, (iii) 577,783 Shares beneficially owned by Fund III, and (iv) 353,184 Shares beneficially owned by Fund IV."}],"balance_after":1994173,"source":{"system":"sec-edgar","filing":"0000929638-25-003712","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1817320/000092963825003712/form4.xml","form_type":"4"}},{"id":1029423,"issuer":{"id":4785,"kind":"organization","name":"MoonLake Immunotherapeutics"},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":2,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":3,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":74740,"kind":"organization","name":"Cormorant Private Healthcare Fund II, LP","position":4,"cik":"0001747677","reported_name":"Cormorant Private Healthcare Fund II, LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":25047,"kind":"organization","name":"Cormorant Private Healthcare Fund III LP","position":5,"cik":"0001817320","reported_name":"Cormorant Private Healthcare Fund III LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":74741,"kind":"organization","name":"Cormorant Private Healthcare Fund IV LP","position":6,"cik":"0001871297","reported_name":"Cormorant Private Healthcare Fund IV LP","relationship":{"other":true,"other_text":"Former 10% Owner"}}],"security":"Class A Ordinary Shares","published_at":"2025-10-01T21:22:38.000Z","date":"2025-09-29","kind":"sale","planned":false,"acquired":false,"shares":2800000,"price":6.61,"value":18508000.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Represents the weighted average sale price of Class A Ordinary Shares (\"Shares\") sold in a series of open market transactions on the transaction date at prices ranging from $6.20 to $7.04 per Share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of Shares sold at each price. All of these Shares were sold by the Master Fund, Fund II, Fund III, Fund IV, and the Account."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Information reported herein relates to Shares owned by Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"), Cormorant Private Healthcare Fund II, LP (\"Fund II\"), Cormorant Private Healthcare Fund III, LP (\"Fund III\"), Cormorant Private Healthcare Fund IV, LP (\"Fund IV\") and a managed account (the \"Account\" and together with the Master Fund, Fund II, Fund III and Fund IV, the \"Funds\")). Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of the Funds. Cormorant Global Healthcare GP, LLC (\"GP LLC\"), Cormorant Private Healthcare GP II, LLC (\"GP II\"), Cormorant Private Healthcare GP III, LLC (\"GP III\") and Cormorant Private Healthcare GP IV, LLC (\"GP IV\") serve as General Partner of the Master Fund, Fund II, Fund III and Fund IV, respectively. Bihua Chen serves as manager of Cormorant, GP LLC, GP II, GP III and GP IV."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Persons disclaims beneficial ownership of the Shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such ordinary shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"Represents (i) 638,740 Shares beneficially owned by the Master Fund, (ii) 424,466 Shares beneficially owned by Fund II, (iii) 577,783 Shares beneficially owned by Fund III, (iv) 353,184 Shares beneficially owned by Fund IV, and (v) 5,827 shares beneficially owned by the Account."}],"balance_after":2000000,"source":{"system":"sec-edgar","filing":"0000929638-25-003712","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1817320/000092963825003712/form4.xml","form_type":"4"}},{"id":1029422,"issuer":{"id":4785,"kind":"organization","name":"MoonLake Immunotherapeutics"},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":2,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":3,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":74740,"kind":"organization","name":"Cormorant Private Healthcare Fund II, LP","position":4,"cik":"0001747677","reported_name":"Cormorant Private Healthcare Fund II, LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":25047,"kind":"organization","name":"Cormorant Private Healthcare Fund III LP","position":5,"cik":"0001817320","reported_name":"Cormorant Private Healthcare Fund III LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":74741,"kind":"organization","name":"Cormorant Private Healthcare Fund IV LP","position":6,"cik":"0001871297","reported_name":"Cormorant Private Healthcare Fund IV LP","relationship":{"other":true,"other_text":"Former 10% Owner"}}],"security":"Class A Ordinary Shares","published_at":"2025-10-01T21:22:38.000Z","date":"2025-09-29","kind":"sale","planned":false,"acquired":false,"shares":3390943,"price":7.58,"value":25703347.94,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents the weighted average sale price of Class A Ordinary Shares (\"Shares\") sold in a series of open market transactions on the transaction date at prices ranging from $7.30 to $8.18 per Share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of Shares sold at each price. All of these Shares were sold by the Master Fund, Fund II, Fund III, Fund IV, and the Account."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Information reported herein relates to Shares owned by Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"), Cormorant Private Healthcare Fund II, LP (\"Fund II\"), Cormorant Private Healthcare Fund III, LP (\"Fund III\"), Cormorant Private Healthcare Fund IV, LP (\"Fund IV\") and a managed account (the \"Account\" and together with the Master Fund, Fund II, Fund III and Fund IV, the \"Funds\")). Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of the Funds. Cormorant Global Healthcare GP, LLC (\"GP LLC\"), Cormorant Private Healthcare GP II, LLC (\"GP II\"), Cormorant Private Healthcare GP III, LLC (\"GP III\") and Cormorant Private Healthcare GP IV, LLC (\"GP IV\") serve as General Partner of the Master Fund, Fund II, Fund III and Fund IV, respectively. Bihua Chen serves as manager of Cormorant, GP LLC, GP II, GP III and GP IV."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Persons disclaims beneficial ownership of the Shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such ordinary shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Represents (i) 1,532,978 Shares beneficially owned by the Master Fund, (ii) 1,018,717 Shares beneficially owned by Fund II, (iii) 1,386,674 Shares beneficially owned by Fund III, (iv) 847,642 Shares beneficially owned by Fund IV, and (v) 13,989 shares beneficially owned by the Account."}],"balance_after":4800000,"source":{"system":"sec-edgar","filing":"0000929638-25-003712","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817320/000092963825003712/form4.xml","form_type":"4"}},{"id":1029421,"issuer":{"id":4785,"kind":"organization","name":"MoonLake Immunotherapeutics"},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":2,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":3,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":74740,"kind":"organization","name":"Cormorant Private Healthcare Fund II, LP","position":4,"cik":"0001747677","reported_name":"Cormorant Private Healthcare Fund II, LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":25047,"kind":"organization","name":"Cormorant Private Healthcare Fund III LP","position":5,"cik":"0001817320","reported_name":"Cormorant Private Healthcare Fund III LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":74741,"kind":"organization","name":"Cormorant Private Healthcare Fund IV LP","position":6,"cik":"0001871297","reported_name":"Cormorant Private Healthcare Fund IV LP","relationship":{"other":true,"other_text":"Former 10% Owner"}}],"security":"Class A Ordinary Shares","published_at":"2025-10-01T21:22:38.000Z","date":"2025-09-29","kind":"sale","planned":false,"acquired":false,"shares":232460,"price":8.4,"value":1952664.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents the weighted average sale price of Class A Ordinary Shares (\"Shares\") sold in a series of open market transactions on the transaction date at prices ranging from $8.20 to $9.02 per Share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of Shares sold at each price. All of these Shares were sold by the Master Fund, Fund II, Fund III, Fund IV, and the Account."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Information reported herein relates to Shares owned by Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"), Cormorant Private Healthcare Fund II, LP (\"Fund II\"), Cormorant Private Healthcare Fund III, LP (\"Fund III\"), Cormorant Private Healthcare Fund IV, LP (\"Fund IV\") and a managed account (the \"Account\" and together with the Master Fund, Fund II, Fund III and Fund IV, the \"Funds\")). Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of the Funds. Cormorant Global Healthcare GP, LLC (\"GP LLC\"), Cormorant Private Healthcare GP II, LLC (\"GP II\"), Cormorant Private Healthcare GP III, LLC (\"GP III\") and Cormorant Private Healthcare GP IV, LLC (\"GP IV\") serve as General Partner of the Master Fund, Fund II, Fund III and Fund IV, respectively. Bihua Chen serves as manager of Cormorant, GP LLC, GP II, GP III and GP IV."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Persons disclaims beneficial ownership of the Shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such ordinary shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Represents (i) 2,615,943 Shares beneficially owned by the Master Fund, (ii) 1,738,386 Shares beneficially owned by Fund II, (iii) 2,366,285 Shares beneficially owned by Fund III, (iv) 1,446,456 Shares beneficially owned by Fund IV, and (v) 23,873 shares beneficially owned by the Account."}],"balance_after":8190943,"source":{"system":"sec-edgar","filing":"0000929638-25-003712","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817320/000092963825003712/form4.xml","form_type":"4"}},{"id":1029420,"issuer":{"id":4785,"kind":"organization","name":"MoonLake Immunotherapeutics"},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":2,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":3,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":74740,"kind":"organization","name":"Cormorant Private Healthcare Fund II, LP","position":4,"cik":"0001747677","reported_name":"Cormorant Private Healthcare Fund II, LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":25047,"kind":"organization","name":"Cormorant Private Healthcare Fund III LP","position":5,"cik":"0001817320","reported_name":"Cormorant Private Healthcare Fund III LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":74741,"kind":"organization","name":"Cormorant Private Healthcare Fund IV LP","position":6,"cik":"0001871297","reported_name":"Cormorant Private Healthcare Fund IV LP","relationship":{"other":true,"other_text":"Former 10% Owner"}}],"security":"Class A Ordinary Shares","published_at":"2025-10-01T21:22:38.000Z","date":"2025-09-29","kind":"sale","planned":false,"acquired":false,"shares":70748,"price":9.38,"value":663616.24,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average sale price of Class A Ordinary Shares (\"Shares\") sold in a series of open market transactions on the transaction date at prices ranging from $9.25 to $9.43 per Share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of Shares sold at each price. All of these Shares were sold by the Master Fund (as defined below) , Fund II (as defined below), Fund III (as defined below), Fund IV (as defined below), and the Account (as defined below)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Information reported herein relates to Shares owned by Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"), Cormorant Private Healthcare Fund II, LP (\"Fund II\"), Cormorant Private Healthcare Fund III, LP (\"Fund III\"), Cormorant Private Healthcare Fund IV, LP (\"Fund IV\") and a managed account (the \"Account\" and together with the Master Fund, Fund II, Fund III and Fund IV, the \"Funds\")). Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of the Funds. Cormorant Global Healthcare GP, LLC (\"GP LLC\"), Cormorant Private Healthcare GP II, LLC (\"GP II\"), Cormorant Private Healthcare GP III, LLC (\"GP III\") and Cormorant Private Healthcare GP IV, LLC (\"GP IV\") serve as General Partner of the Master Fund, Fund II, Fund III and Fund IV, respectively. Bihua Chen serves as manager of Cormorant, GP LLC, GP II, GP III and GP IV."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Persons disclaims beneficial ownership of the Shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such ordinary shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents (i) 2,690,183 Shares beneficially owned by the Master Fund, (ii) 1,787,722 Shares beneficially owned by Fund II, (iii) 2,433,441 Shares beneficially owned by Fund III, (iv) 1,487,507 Shares beneficially owned by Fund IV, and (v) 24,550 shares beneficially owned by the Account."}],"balance_after":8423403,"source":{"system":"sec-edgar","filing":"0000929638-25-003712","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817320/000092963825003712/form4.xml","form_type":"4"}},{"id":1067921,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class B ordinary shares","published_at":"2025-08-13T12:28:26.000Z","date":"2025-08-11","kind":"exercise","planned":false,"acquired":false,"shares":4172126,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Helix Class B ordinary shares have no expiration date and automatically convert into Class A ordinary shares at the time of Helix's initial business combination as described under the heading \"Description of Securities\" in Helix's registration statement on Form S-1 (File No. 333-276591)."},{"field":"kind","element":"transactionCoding","label":"F3","text":"In connection with and prior to the closing of the Business Combination, among other things, (i) each of Helix's Class B ordinary shares converted into one Helix Class A ordinary share, on a one-for-one basis, (ii) Helix migrated to and domesticated as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law, as amended, and the Cayman Islands Companies Act (As Revised) (the \"Domestication\"), and (iii) as a result of the Domestication, each Class A ordinary share of Helix converted into one share of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\"), on a one-for-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"In connection with and prior to the closing of the Business Combination, among other things, (i) each of Helix's Class B ordinary shares converted into one Helix Class A ordinary share, on a one-for-one basis, (ii) Helix migrated to and domesticated as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law, as amended, and the Cayman Islands Companies Act (As Revised) (the \"Domestication\"), and (iii) as a result of the Domestication, each Class A ordinary share of Helix converted into one share of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\"), on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Helix Class B ordinary shares have no expiration date and automatically convert into Class A ordinary shares at the time of Helix's initial business combination as described under the heading \"Description of Securities\" in Helix's registration statement on Form S-1 (File No. 333-276591)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Helix Class B ordinary shares have no expiration date and automatically convert into Class A ordinary shares at the time of Helix's initial business combination as described under the heading \"Description of Securities\" in Helix's registration statement on Form S-1 (File No. 333-276591)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"Sponsor is the record holder of the securities reported herein. Fund III, Fund V, and Master Fund are the members of Sponsor. Bihua Chen is the manager of Sponsor and has voting and investment discretion with respect to the shares held of record by Sponsor. Each of Fund III, Fund V, Master Fund and Ms. Chen disclaims any beneficial ownership of the securities held by Sponsor other than to the extent of any pecuniary interest she or it may have therein, directly or indirectly."}],"balance_after":0,"derivative":{"underlying":"Class A ordinary shares","underlying_shares":4172126},"source":{"system":"sec-edgar","filing":"0001213900-25-075305","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000121390025075305/ownership.xml","form_type":"4"}},{"id":1067920,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class B ordinary shares","published_at":"2025-08-13T12:28:26.000Z","date":"2025-08-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":307874,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Helix Class B ordinary shares have no expiration date and automatically convert into Class A ordinary shares at the time of Helix's initial business combination as described under the heading \"Description of Securities\" in Helix's registration statement on Form S-1 (File No. 333-276591)."},{"field":"kind","element":"transactionCoding","label":"F1","text":"In connection with and prior to the closing of the business combination (the \"Business Combination\") between the Issuer (which was formerly known as Helix Acquisition Corp. II, \"Helix\") and TheRas, Inc. (\"Legacy BBOT\"), Helix Holdings II LLC (the \"Sponsor\") forfeited 307,874 Helix Class B ordinary shares for no consideration pursuant to the terms of the Sponsor Support Agreement dated February 28, 2025, between Sponsor, Helix, and Legacy BBOT (the \"Sponsor Support Agreement\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Helix Class B ordinary shares have no expiration date and automatically convert into Class A ordinary shares at the time of Helix's initial business combination as described under the heading \"Description of Securities\" in Helix's registration statement on Form S-1 (File No. 333-276591)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Helix Class B ordinary shares have no expiration date and automatically convert into Class A ordinary shares at the time of Helix's initial business combination as described under the heading \"Description of Securities\" in Helix's registration statement on Form S-1 (File No. 333-276591)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"Sponsor is the record holder of the securities reported herein. Fund III, Fund V, and Master Fund are the members of Sponsor. Bihua Chen is the manager of Sponsor and has voting and investment discretion with respect to the shares held of record by Sponsor. Each of Fund III, Fund V, Master Fund and Ms. Chen disclaims any beneficial ownership of the securities held by Sponsor other than to the extent of any pecuniary interest she or it may have therein, directly or indirectly."}],"balance_after":4172126,"derivative":{"underlying":"Class A ordinary shares","underlying_shares":307874},"source":{"system":"sec-edgar","filing":"0001213900-25-075305","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000121390025075305/ownership.xml","form_type":"4"}},{"id":1067919,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-08-13T12:28:26.000Z","date":"2025-08-11","kind":"grant","planned":false,"acquired":true,"shares":284571,"ownership":{"direct":false,"nature":"Via Master Fund"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"Upon the closing of the Business Combination, as contemplated by the terms of the Business Combination Agreement, dated as of February 28, 2025 (as amended, the \"Business Combination Agreement\"), by and among Helix, Legacy BBOT, and Helix Merger Sub, Inc., the owners of Legacy BBOT equity as of immediately prior to the closing, including Fund V, Master Fund, and Cormorant Private Healthcare Fund IV, LP (\"Fund IV\"), received as consideration therefor, shares of common stock of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Upon the closing of the Business Combination, as contemplated by the terms of the Business Combination Agreement, dated as of February 28, 2025 (as amended, the \"Business Combination Agreement\"), by and among Helix, Legacy BBOT, and Helix Merger Sub, Inc., the owners of Legacy BBOT equity as of immediately prior to the closing, including Fund V, Master Fund, and Cormorant Private Healthcare Fund IV, LP (\"Fund IV\"), received as consideration therefor, shares of common stock of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"Cormorant Asset Management, LP serves as the investment manager to Fund III, Fund IV, Fund V, and Master Fund (collectively, the \"Cormorant Funds\"). Cormorant Private Healthcare GP III, LLC (\"GP III\") is the general partner of Fund III; Cormorant Private Healthcare GP IV, LLC (\"GP IV\") is the general partner of Fund IV; Cormorant Private Healthcare GP V, LLC (\"GP V\") is the general partner of Fund V; and Cormorant Global Healthcare GP, LLC (\"Global GP\") is the general partner of the Master Fund. Bihua Chen serves as the managing member of GP III, GP IV, GP V, and Global GP, and as the general partner of Cormorant Asset Management, LP. Accordingly, Ms. Chen has voting and investment discretion with respect to the shares held by each of the Cormorant Funds and Cormorant Asset Management, LP. Ms. Chen disclaims any beneficial ownership of the securities held by each of the Cormorant Funds other than to the extent of any pecuniary interest she may have therein, directly or indirectly."}],"balance_after":5952356,"source":{"system":"sec-edgar","filing":"0001213900-25-075305","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000121390025075305/ownership.xml","form_type":"4"}},{"id":1067918,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-08-13T12:28:26.000Z","date":"2025-08-11","kind":"grant","planned":false,"acquired":true,"shares":1762760,"ownership":{"direct":false,"nature":"Via Fund V"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"Upon the closing of the Business Combination, as contemplated by the terms of the Business Combination Agreement, dated as of February 28, 2025 (as amended, the \"Business Combination Agreement\"), by and among Helix, Legacy BBOT, and Helix Merger Sub, Inc., the owners of Legacy BBOT equity as of immediately prior to the closing, including Fund V, Master Fund, and Cormorant Private Healthcare Fund IV, LP (\"Fund IV\"), received as consideration therefor, shares of common stock of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Upon the closing of the Business Combination, as contemplated by the terms of the Business Combination Agreement, dated as of February 28, 2025 (as amended, the \"Business Combination Agreement\"), by and among Helix, Legacy BBOT, and Helix Merger Sub, Inc., the owners of Legacy BBOT equity as of immediately prior to the closing, including Fund V, Master Fund, and Cormorant Private Healthcare Fund IV, LP (\"Fund IV\"), received as consideration therefor, shares of common stock of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"Cormorant Asset Management, LP serves as the investment manager to Fund III, Fund IV, Fund V, and Master Fund (collectively, the \"Cormorant Funds\"). Cormorant Private Healthcare GP III, LLC (\"GP III\") is the general partner of Fund III; Cormorant Private Healthcare GP IV, LLC (\"GP IV\") is the general partner of Fund IV; Cormorant Private Healthcare GP V, LLC (\"GP V\") is the general partner of Fund V; and Cormorant Global Healthcare GP, LLC (\"Global GP\") is the general partner of the Master Fund. Bihua Chen serves as the managing member of GP III, GP IV, GP V, and Global GP, and as the general partner of Cormorant Asset Management, LP. Accordingly, Ms. Chen has voting and investment discretion with respect to the shares held by each of the Cormorant Funds and Cormorant Asset Management, LP. Ms. Chen disclaims any beneficial ownership of the securities held by each of the Cormorant Funds other than to the extent of any pecuniary interest she may have therein, directly or indirectly."}],"balance_after":3305470,"source":{"system":"sec-edgar","filing":"0001213900-25-075305","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000121390025075305/ownership.xml","form_type":"4"}},{"id":1067917,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-08-13T12:28:26.000Z","date":"2025-08-11","kind":"grant","planned":false,"acquired":true,"shares":1905046,"ownership":{"direct":false,"nature":"Via Fund IV"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"Upon the closing of the Business Combination, as contemplated by the terms of the Business Combination Agreement, dated as of February 28, 2025 (as amended, the \"Business Combination Agreement\"), by and among Helix, Legacy BBOT, and Helix Merger Sub, Inc., the owners of Legacy BBOT equity as of immediately prior to the closing, including Fund V, Master Fund, and Cormorant Private Healthcare Fund IV, LP (\"Fund IV\"), received as consideration therefor, shares of common stock of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Upon the closing of the Business Combination, as contemplated by the terms of the Business Combination Agreement, dated as of February 28, 2025 (as amended, the \"Business Combination Agreement\"), by and among Helix, Legacy BBOT, and Helix Merger Sub, Inc., the owners of Legacy BBOT equity as of immediately prior to the closing, including Fund V, Master Fund, and Cormorant Private Healthcare Fund IV, LP (\"Fund IV\"), received as consideration therefor, shares of common stock of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"Cormorant Asset Management, LP serves as the investment manager to Fund III, Fund IV, Fund V, and Master Fund (collectively, the \"Cormorant Funds\"). Cormorant Private Healthcare GP III, LLC (\"GP III\") is the general partner of Fund III; Cormorant Private Healthcare GP IV, LLC (\"GP IV\") is the general partner of Fund IV; Cormorant Private Healthcare GP V, LLC (\"GP V\") is the general partner of Fund V; and Cormorant Global Healthcare GP, LLC (\"Global GP\") is the general partner of the Master Fund. Bihua Chen serves as the managing member of GP III, GP IV, GP V, and Global GP, and as the general partner of Cormorant Asset Management, LP. Accordingly, Ms. Chen has voting and investment discretion with respect to the shares held by each of the Cormorant Funds and Cormorant Asset Management, LP. Ms. Chen disclaims any beneficial ownership of the securities held by each of the Cormorant Funds other than to the extent of any pecuniary interest she may have therein, directly or indirectly."}],"balance_after":1905046,"source":{"system":"sec-edgar","filing":"0001213900-25-075305","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000121390025075305/ownership.xml","form_type":"4"}},{"id":1067916,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-08-13T12:28:26.000Z","date":"2025-08-11","kind":"grant","planned":false,"acquired":true,"shares":5598425,"price":10.7173,"value":60000000.2525,"ownership":{"direct":false,"nature":"Via Master Fund"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"In connection with and immediately prior to the closing of the Business Combination, pursuant to the terms of the Subscription Agreement, Cormorant Global Healthcare Master Fund, LP (\"Master Fund\"), which is an investment vehicle managed by Cormorant Asset Management, LP, purchased from the Issuer 5,598,425 shares of Common Stock at a purchase price of $10.7173 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"Cormorant Asset Management, LP serves as the investment manager to Fund III, Fund IV, Fund V, and Master Fund (collectively, the \"Cormorant Funds\"). Cormorant Private Healthcare GP III, LLC (\"GP III\") is the general partner of Fund III; Cormorant Private Healthcare GP IV, LLC (\"GP IV\") is the general partner of Fund IV; Cormorant Private Healthcare GP V, LLC (\"GP V\") is the general partner of Fund V; and Cormorant Global Healthcare GP, LLC (\"Global GP\") is the general partner of the Master Fund. Bihua Chen serves as the managing member of GP III, GP IV, GP V, and Global GP, and as the general partner of Cormorant Asset Management, LP. Accordingly, Ms. Chen has voting and investment discretion with respect to the shares held by each of the Cormorant Funds and Cormorant Asset Management, LP. Ms. Chen disclaims any beneficial ownership of the securities held by each of the Cormorant Funds other than to the extent of any pecuniary interest she may have therein, directly or indirectly."}],"balance_after":5667785,"source":{"system":"sec-edgar","filing":"0001213900-25-075305","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000121390025075305/ownership.xml","form_type":"4"}},{"id":1067915,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-08-13T12:28:26.000Z","date":"2025-08-11","kind":"grant","planned":false,"acquired":true,"shares":639110,"price":10.7173,"value":6849533.603,"ownership":{"direct":false,"nature":"Via Fund V"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"In connection with and immediately prior to the closing of the Business Combination, pursuant to the terms of the Subscription Agreement, Cormorant Private Healthcare Fund V, LP (\"Fund V\"), which is an investment vehicle managed by Cormorant Asset Management, LP, purchased from the Issuer 639,110 shares of Common Stock at a purchase price of $10.7173 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"Cormorant Asset Management, LP serves as the investment manager to Fund III, Fund IV, Fund V, and Master Fund (collectively, the \"Cormorant Funds\"). Cormorant Private Healthcare GP III, LLC (\"GP III\") is the general partner of Fund III; Cormorant Private Healthcare GP IV, LLC (\"GP IV\") is the general partner of Fund IV; Cormorant Private Healthcare GP V, LLC (\"GP V\") is the general partner of Fund V; and Cormorant Global Healthcare GP, LLC (\"Global GP\") is the general partner of the Master Fund. Bihua Chen serves as the managing member of GP III, GP IV, GP V, and Global GP, and as the general partner of Cormorant Asset Management, LP. Accordingly, Ms. Chen has voting and investment discretion with respect to the shares held by each of the Cormorant Funds and Cormorant Asset Management, LP. Ms. Chen disclaims any beneficial ownership of the securities held by each of the Cormorant Funds other than to the extent of any pecuniary interest she may have therein, directly or indirectly."}],"balance_after":1542710,"source":{"system":"sec-edgar","filing":"0001213900-25-075305","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000121390025075305/ownership.xml","form_type":"4"}},{"id":1067914,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-08-13T12:28:26.000Z","date":"2025-08-11","kind":"grant","planned":false,"acquired":true,"shares":760496,"price":10.7173,"value":8150463.7808,"ownership":{"direct":false,"nature":"Via Fund III"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"In connection with and immediately prior to the closing of the Business Combination, pursuant to the terms of a subscription agreement dated February 28, 2025 between Helix and Cormorant Asset Management, LP (the \"Subscription Agreement\"), Cormorant Private Healthcare Fund III, LP (\"Fund III\"), which is an investment vehicle managed by Cormorant Asset Management, LP, purchased from the Issuer 760,496 shares of Common Stock at a purchase price of $10.7173 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"Cormorant Asset Management, LP serves as the investment manager to Fund III, Fund IV, Fund V, and Master Fund (collectively, the \"Cormorant Funds\"). Cormorant Private Healthcare GP III, LLC (\"GP III\") is the general partner of Fund III; Cormorant Private Healthcare GP IV, LLC (\"GP IV\") is the general partner of Fund IV; Cormorant Private Healthcare GP V, LLC (\"GP V\") is the general partner of Fund V; and Cormorant Global Healthcare GP, LLC (\"Global GP\") is the general partner of the Master Fund. Bihua Chen serves as the managing member of GP III, GP IV, GP V, and Global GP, and as the general partner of Cormorant Asset Management, LP. Accordingly, Ms. Chen has voting and investment discretion with respect to the shares held by each of the Cormorant Funds and Cormorant Asset Management, LP. Ms. Chen disclaims any beneficial ownership of the securities held by each of the Cormorant Funds other than to the extent of any pecuniary interest she may have therein, directly or indirectly."}],"balance_after":2187536,"source":{"system":"sec-edgar","filing":"0001213900-25-075305","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000121390025075305/ownership.xml","form_type":"4"}},{"id":1067913,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-08-13T12:28:26.000Z","date":"2025-08-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":152940,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Via Helix Holdings II LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"In connection with and immediately prior to the closing of the Business Combination, the Sponsor forfeited 152,940 shares of Common Stock for no consideration, pursuant to the terms of the Sponsor Support Agreement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"Sponsor is the record holder of the securities reported herein. Fund III, Fund V, and Master Fund are the members of Sponsor. Bihua Chen is the manager of Sponsor and has voting and investment discretion with respect to the shares held of record by Sponsor. Each of Fund III, Fund V, Master Fund and Ms. Chen disclaims any beneficial ownership of the securities held by Sponsor other than to the extent of any pecuniary interest she or it may have therein, directly or indirectly."}],"balance_after":4528186,"source":{"system":"sec-edgar","filing":"0001213900-25-075305","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000121390025075305/ownership.xml","form_type":"4"}},{"id":1067912,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-08-13T12:28:26.000Z","date":"2025-08-11","kind":"exercise","planned":false,"acquired":true,"shares":4172126,"ownership":{"direct":false,"nature":"Via Helix Holdings II LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"In connection with and prior to the closing of the Business Combination, among other things, (i) each of Helix's Class B ordinary shares converted into one Helix Class A ordinary share, on a one-for-one basis, (ii) Helix migrated to and domesticated as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law, as amended, and the Cayman Islands Companies Act (As Revised) (the \"Domestication\"), and (iii) as a result of the Domestication, each Class A ordinary share of Helix converted into one share of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\"), on a one-for-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"In connection with and prior to the closing of the Business Combination, among other things, (i) each of Helix's Class B ordinary shares converted into one Helix Class A ordinary share, on a one-for-one basis, (ii) Helix migrated to and domesticated as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law, as amended, and the Cayman Islands Companies Act (As Revised) (the \"Domestication\"), and (iii) as a result of the Domestication, each Class A ordinary share of Helix converted into one share of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\"), on a one-for-one basis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"Sponsor is the record holder of the securities reported herein. Fund III, Fund V, and Master Fund are the members of Sponsor. Bihua Chen is the manager of Sponsor and has voting and investment discretion with respect to the shares held of record by Sponsor. Each of Fund III, Fund V, Master Fund and Ms. Chen disclaims any beneficial ownership of the securities held by Sponsor other than to the extent of any pecuniary interest she or it may have therein, directly or indirectly."}],"balance_after":4681126,"source":{"system":"sec-edgar","filing":"0001213900-25-075305","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000121390025075305/ownership.xml","form_type":"4"}},{"id":1111890,"issuer":{"id":6606,"kind":"organization","name":"Biomea Fusion, Inc."},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"director":true,"ten_percent_owner":true}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":2,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"ten_percent_owner":true}},{"id":25047,"kind":"organization","name":"Cormorant Private Healthcare Fund III LP","position":3,"cik":"0001817320","reported_name":"Cormorant Private Healthcare Fund III LP","relationship":{"ten_percent_owner":true}},{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":4,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"ten_percent_owner":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-13T20:02:39.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":91970,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The options vest in full upon the earlier of (i) the one-year anniversary of the date of grant or (ii) immediately prior to the annual meeting of the Issuer's stockholders that occurs following the date of grant, subject to Ms. Chen's continuing service to the Issuer through such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Stock options granted to Bihua Chen, in her capacity as a director of the Issuer."}],"balance_after":91970,"derivative":{"exercise_price":2.5,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":91970},"source":{"system":"sec-edgar","filing":"0000929638-25-002234","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1817320/000092963825002234/form4.xml","form_type":"4"}},{"id":1142937,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":2,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":25047,"kind":"organization","name":"Cormorant Private Healthcare Fund III LP","position":3,"cik":"0001817320","reported_name":"Cormorant Private Healthcare Fund III LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":74741,"kind":"organization","name":"Cormorant Private Healthcare Fund IV LP","position":4,"cik":"0001871297","reported_name":"Cormorant Private Healthcare Fund IV LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":25048,"kind":"organization","name":"Cormorant Private Healthcare Fund V LP","position":5,"cik":"0001969296","reported_name":"Cormorant Private Healthcare Fund V LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":25044,"kind":"person","name":"Chen Bihua","position":6,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"other":true,"other_text":"Former 10% Owner"}}],"security":"Class A Common Stock","published_at":"2025-05-19T21:33:06.000Z","date":"2025-05-15","kind":"sale","planned":false,"acquired":false,"shares":1813439,"price":1.8545,"value":3363022.6255,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of Class A Common Stock (the \"shares\") sold in a series of open market transactions on the transaction date ranging from $1.85 to $2.03 per share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Cormorant Asset Management, LP serves as the investment manager to Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"), Cormorant Private Healthcare Fund III, LP (\"Fund III\"), Cormorant Private Healthcare Fund IV, LP (\"Fund IV\") and Cormorant Private Healthcare Fund V, LP (\"Fund V\"). Cormorant Global Healthcare GP, LLC, Cormorant Private Healthcare GP III, LLC, Cormorant Private Healthcare GP IV, LLC and Cormorant Private Healthcare GP V, LLC serve as the general partners of the Master Fund, Fund III, Fund IV and Fund V, respectively. Bihua Chen serves as the managing member of Cormorant Global Healthcare GP, LLC, Cormorant Private Healthcare GP III, LLC, Cormorant Private Healthcare GP IV, LLC and Cormorant Private Healthcare GP V, LLC, and the general partner of Cormorant Asset Management, LP."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000929638-25-001950","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817320/000092963825001950/form4.xml","form_type":"4"}},{"id":1149321,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"ten_percent_owner":true}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":2,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"ten_percent_owner":true}},{"id":25047,"kind":"organization","name":"Cormorant Private Healthcare Fund III LP","position":3,"cik":"0001817320","reported_name":"Cormorant Private Healthcare Fund III LP","relationship":{"ten_percent_owner":true}},{"id":74741,"kind":"organization","name":"Cormorant Private Healthcare Fund IV LP","position":4,"cik":"0001871297","reported_name":"Cormorant Private Healthcare Fund IV LP","relationship":{"ten_percent_owner":true}},{"id":25048,"kind":"organization","name":"Cormorant Private Healthcare Fund V LP","position":5,"cik":"0001969296","reported_name":"Cormorant Private Healthcare Fund V LP","relationship":{"ten_percent_owner":true}},{"id":25044,"kind":"person","name":"Chen Bihua","position":6,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"ten_percent_owner":true}}],"security":"Class A Common Stock","published_at":"2025-05-14T20:36:04.000Z","date":"2025-05-12","kind":"sale","planned":false,"acquired":false,"shares":24300,"price":1.985,"value":48235.5,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Cormorant Asset Management, LP serves as the investment manager to Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"), Cormorant Private Healthcare Fund III, LP (\"Fund III\"), Cormorant Private Healthcare Fund IV, LP (\"Fund IV\") and Cormorant Private Healthcare Fund V, LP (\"Fund V\"). Cormorant Global Healthcare GP, LLC, Cormorant Private Healthcare GP III, LLC, Cormorant Private Healthcare GP IV, LLC and Cormorant Private Healthcare GP V, LLC serve as the general partners of the Master Fund, Fund III, Fund IV and Fund V, respectively. Bihua Chen serves as the managing member of Cormorant Global Healthcare GP, LLC, Cormorant Private Healthcare GP III, LLC, Cormorant Private Healthcare GP IV, LLC and Cormorant Private Healthcare GP V, LLC, and the general partner of Cormorant Asset Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents (i) 429,934 shares of Class A Common Stock beneficially owned by the Master Fund, (ii) 1,099,451 shares of Class A Common Stock beneficially owned by Fund III, (iii) 234,125 shares of Class A Common Stock beneficially owned by Fund IV, and (iv) 49,929 shares of Class A Common Stock beneficially owned by Fund V."}],"balance_after":1813439,"source":{"system":"sec-edgar","filing":"0000929638-25-001870","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817320/000092963825001870/form4.xml","form_type":"4"}},{"id":1258695,"issuer":{"id":6598,"kind":"organization","name":"Aardvark Therapeutics, Inc.","symbol":"AARD"},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":25044,"kind":"person","name":"Chen Bihua","position":2,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"other":true,"other_text":"Former 10% Owner"}}],"security":"Series C Convertible Preferred Stock","published_at":"2025-02-19T21:02:07.000Z","date":"2025-02-14","kind":"exercise","planned":false,"acquired":false,"shares":6780810,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering of Common Stock on February 14, 2025, the Series C Convertible Preferred Stock automatically converted into Common Stock at a 1-for-8.474 conversion ratio, after giving effect to a reverse stock split effected by the Issuer on February 5, 2025, for an aggregate of 800,189 shares of Common Stock. The Series C Convertible Preferred Stock had no expiration date."},{"field":"shares","element":"transactionShares","label":"F1","text":"Upon the closing of the Issuer's initial public offering of Common Stock on February 14, 2025, the Series C Convertible Preferred Stock automatically converted into Common Stock at a 1-for-8.474 conversion ratio, after giving effect to a reverse stock split effected by the Issuer on February 5, 2025, for an aggregate of 800,189 shares of Common Stock. The Series C Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the Issuer's initial public offering of Common Stock on February 14, 2025, the Series C Convertible Preferred Stock automatically converted into Common Stock at a 1-for-8.474 conversion ratio, after giving effect to a reverse stock split effected by the Issuer on February 5, 2025, for an aggregate of 800,189 shares of Common Stock. The Series C Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering of Common Stock on February 14, 2025, the Series C Convertible Preferred Stock automatically converted into Common Stock at a 1-for-8.474 conversion ratio, after giving effect to a reverse stock split effected by the Issuer on February 5, 2025, for an aggregate of 800,189 shares of Common Stock. The Series C Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering of Common Stock on February 14, 2025, the Series C Convertible Preferred Stock automatically converted into Common Stock at a 1-for-8.474 conversion ratio, after giving effect to a reverse stock split effected by the Issuer on February 5, 2025, for an aggregate of 800,189 shares of Common Stock. The Series C Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Upon the closing of the Issuer's initial public offering of Common Stock on February 14, 2025, the Series C Convertible Preferred Stock automatically converted into Common Stock at a 1-for-8.474 conversion ratio, after giving effect to a reverse stock split effected by the Issuer on February 5, 2025, for an aggregate of 800,189 shares of Common Stock. The Series C Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\") and Cormorant Private Healthcare Fund V, LP (\"Fund V\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\") serves as general partner of the Master Fund, and Cormorant Private Healthcare V GP, LLC (\"GP V LLC\") serves as general partner of Fund V. Bihua Chen serves as the managing member of GP LLC, GP V LLC and the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":800189},"source":{"system":"sec-edgar","filing":"0000929638-25-000822","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1583977/000092963825000822/form4.xml","form_type":"4"}},{"id":1258694,"issuer":{"id":6598,"kind":"organization","name":"Aardvark Therapeutics, Inc.","symbol":"AARD"},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":25044,"kind":"person","name":"Chen Bihua","position":2,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock","published_at":"2025-02-19T21:02:07.000Z","date":"2025-02-14","kind":"purchase","planned":false,"acquired":true,"shares":187500,"price":16,"value":3000000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\") and Cormorant Private Healthcare Fund V, LP (\"Fund V\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\") serves as general partner of the Master Fund, and Cormorant Private Healthcare V GP, LLC (\"GP V LLC\") serves as general partner of Fund V. Bihua Chen serves as the managing member of GP LLC, GP V LLC and the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents 298,486 and 689,203 shares of Common Stock beneficially owned by the Master Fund and Fund V, respectively."}],"balance_after":987689,"source":{"system":"sec-edgar","filing":"0000929638-25-000822","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1583977/000092963825000822/form4.xml","form_type":"4"}},{"id":1258693,"issuer":{"id":6598,"kind":"organization","name":"Aardvark Therapeutics, Inc.","symbol":"AARD"},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":25044,"kind":"person","name":"Chen Bihua","position":2,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock","published_at":"2025-02-19T21:02:07.000Z","date":"2025-02-14","kind":"exercise","planned":false,"acquired":true,"shares":800189,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the Issuer's initial public offering of Common Stock on February 14, 2025, the Series C Convertible Preferred Stock automatically converted into Common Stock at a 1-for-8.474 conversion ratio, after giving effect to a reverse stock split effected by the Issuer on February 5, 2025, for an aggregate of 800,189 shares of Common Stock. The Series C Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\") and Cormorant Private Healthcare Fund V, LP (\"Fund V\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\") serves as general partner of the Master Fund, and Cormorant Private Healthcare V GP, LLC (\"GP V LLC\") serves as general partner of Fund V. Bihua Chen serves as the managing member of GP LLC, GP V LLC and the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."}],"balance_after":800189,"source":{"system":"sec-edgar","filing":"0000929638-25-000822","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583977/000092963825000822/form4.xml","form_type":"4"}},{"id":1276752,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO and Chairperson"}}],"security":"Class B Ordinary Shares","published_at":"2025-02-10T22:06:42.000Z","date":"2025-02-08","kind":"other","planned":false,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Class B ordinary shares will automatically convertible into Class A ordinary shares at the time of the Issuer's initial business combination on a one-for-one basis (unless otherwise provided in Issuer's initial business combination agreement), subject to adjustment for share subdivisions, share consolidations, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights as described under the heading \"Description of Securities--Founder Shares and Private Placement Shares\" in the Issuer's registration statement on Form S-1 (File No. 333-276591) and have no expiration date."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On February 8, 2025, Helix Holdings II LLC (the \"Sponsor\") transferred 30,000 Class B Ordinary Shares owned by it to Albert A. Holman, III in connection with his appointment as a director of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Class B ordinary shares will automatically convertible into Class A ordinary shares at the time of the Issuer's initial business combination on a one-for-one basis (unless otherwise provided in Issuer's initial business combination agreement), subject to adjustment for share subdivisions, share consolidations, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights as described under the heading \"Description of Securities--Founder Shares and Private Placement Shares\" in the Issuer's registration statement on Form S-1 (File No. 333-276591) and have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Class B ordinary shares will automatically convertible into Class A ordinary shares at the time of the Issuer's initial business combination on a one-for-one basis (unless otherwise provided in Issuer's initial business combination agreement), subject to adjustment for share subdivisions, share consolidations, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights as described under the heading \"Description of Securities--Founder Shares and Private Placement Shares\" in the Issuer's registration statement on Form S-1 (File No. 333-276591) and have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Sponsor is the record holder of such securities. Cormorant Private Healthcare Fund III, LP, a Delaware limited partnership, Cormorant Private Healthcare Fund V, LP, a Delaware limited partnership, and Cormorant Global Healthcare Master Fund, LP, a Cayman Islands limited partnership, are the members of the Sponsor. Bihua Chen is the manager of the Sponsor and is the managing member of each of the three members of the Sponsor and has voting and investment discretion with respect to the ordinary shares held of record by the Sponsor. Ms. Chen disclaims any beneficial ownership of the securities held by the Sponsor other than to the extent of any pecuniary interest she may have therein, directly or indirectly."}],"balance_after":4480000,"derivative":{"underlying":"Class A Ordinary Shares","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001213900-25-011810","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000121390025011810/ownership.xml","form_type":"4"}},{"id":1374685,"issuer":{"id":5231,"kind":"organization","name":"BRIGHT MINDS BIOSCIENCES INC."},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"ten_percent_owner":true}},{"id":25044,"kind":"person","name":"Chen Bihua","position":2,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"ten_percent_owner":true}}],"security":"Common Shares","published_at":"2024-11-06T21:20:48.000Z","date":"2024-11-04","kind":"purchase","planned":false,"acquired":true,"shares":184331,"price":21.7,"value":3999982.7,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\") serves as general partner of the Master Fund. Bihua Chen serves as the managing member of GP LLC and the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.  All of the shares reported herein are held for the account of the Master Fund."}],"balance_after":1059331,"source":{"system":"sec-edgar","filing":"0000929638-24-003752","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1827401/000092963824003752/form4.xml","form_type":"4"}},{"id":1385363,"issuer":{"id":5231,"kind":"organization","name":"BRIGHT MINDS BIOSCIENCES INC."},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"ten_percent_owner":true}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":2,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"ten_percent_owner":true}},{"id":25044,"kind":"person","name":"Chen Bihua","position":3,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"ten_percent_owner":true}}],"security":"Common Shares","published_at":"2024-10-17T21:11:29.000Z","date":"2024-10-16","kind":"purchase","planned":false,"acquired":true,"shares":3107,"price":25.222,"value":78364.754,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F12","text":"Represents the weighted average sale price of common shares purchased in a series of open market transactions on the transaction date at prices ranging from $24.78 to $25.705 per share. The Reporting Persons undertake to provide, upon request by the staff of the SEC, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of these shares were purchased by the Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\") serves as general partner of the Master Fund. Bihua Chen serves as the managing member of GP LLC and the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."}],"balance_after":875000,"source":{"system":"sec-edgar","filing":"0000929638-24-003542","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1827401/000092963824003542/form4.xml","form_type":"4"}},{"id":1385362,"issuer":{"id":5231,"kind":"organization","name":"BRIGHT MINDS BIOSCIENCES INC."},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"ten_percent_owner":true}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":2,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"ten_percent_owner":true}},{"id":25044,"kind":"person","name":"Chen Bihua","position":3,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"ten_percent_owner":true}}],"security":"Common Shares","published_at":"2024-10-17T21:11:29.000Z","date":"2024-10-16","kind":"purchase","planned":false,"acquired":true,"shares":7150,"price":24.03,"value":171814.5,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F11","text":"Represents the weighted average sale price of common shares purchased in a series of open market transactions on the transaction date at prices ranging from $23.775 to $24.74 per share. The Reporting Persons undertake to provide, upon request by the staff of the SEC, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of these shares were purchased by the Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\") serves as general partner of the Master Fund. Bihua Chen serves as the managing member of GP LLC and the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."}],"balance_after":871893,"source":{"system":"sec-edgar","filing":"0000929638-24-003542","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1827401/000092963824003542/form4.xml","form_type":"4"}},{"id":1385361,"issuer":{"id":5231,"kind":"organization","name":"BRIGHT MINDS BIOSCIENCES INC."},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"ten_percent_owner":true}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":2,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"ten_percent_owner":true}},{"id":25044,"kind":"person","name":"Chen Bihua","position":3,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"ten_percent_owner":true}}],"security":"Common Shares","published_at":"2024-10-17T21:11:29.000Z","date":"2024-10-16","kind":"purchase","planned":false,"acquired":true,"shares":39743,"price":23.215,"value":922633.745,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Represents the weighted average sale price of common shares purchased in a series of open market transactions on the transaction date at prices ranging from $22.76 to $23.73 per share. The Reporting Persons undertake to provide, upon request by the staff of the SEC, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of these shares were purchased by the Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\") serves as general partner of the Master Fund. Bihua Chen serves as the managing member of GP LLC and the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."}],"balance_after":864743,"source":{"system":"sec-edgar","filing":"0000929638-24-003542","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1827401/000092963824003542/form4.xml","form_type":"4"}},{"id":1385360,"issuer":{"id":5231,"kind":"organization","name":"BRIGHT MINDS BIOSCIENCES INC."},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"ten_percent_owner":true}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":2,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"ten_percent_owner":true}},{"id":25044,"kind":"person","name":"Chen Bihua","position":3,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"ten_percent_owner":true}}],"security":"Common Shares","published_at":"2024-10-17T21:11:29.000Z","date":"2024-10-15","kind":"purchase","planned":false,"acquired":true,"shares":4609,"price":12.3513,"value":56927.1417,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Represents the weighted average sale price of common shares purchased in a series of open market transactions on the transaction date at prices ranging from $12.16 to $12.50 per share. The Reporting Persons undertake to provide, upon request by the staff of the SEC, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of these shares were purchased by the Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\") serves as general partner of the Master Fund. Bihua Chen serves as the managing member of GP LLC and the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."}],"balance_after":825000,"source":{"system":"sec-edgar","filing":"0000929638-24-003542","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1827401/000092963824003542/form4.xml","form_type":"4"}},{"id":1385359,"issuer":{"id":5231,"kind":"organization","name":"BRIGHT MINDS BIOSCIENCES INC."},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"ten_percent_owner":true}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":2,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"ten_percent_owner":true}},{"id":25044,"kind":"person","name":"Chen Bihua","position":3,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"ten_percent_owner":true}}],"security":"Common Shares","published_at":"2024-10-17T21:11:29.000Z","date":"2024-10-15","kind":"purchase","planned":false,"acquired":true,"shares":19169,"price":11.7169,"value":224601.2561,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Represents the weighted average sale price of common shares purchased in a series of open market transactions on the transaction date at prices ranging from $11.18 to $12.125 per share. The Reporting Persons undertake to provide, upon request by the staff of the SEC, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of these shares were purchased by the Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\") serves as general partner of the Master Fund. Bihua Chen serves as the managing member of GP LLC and the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."}],"balance_after":820391,"source":{"system":"sec-edgar","filing":"0000929638-24-003542","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1827401/000092963824003542/form4.xml","form_type":"4"}},{"id":1385358,"issuer":{"id":5231,"kind":"organization","name":"BRIGHT MINDS BIOSCIENCES INC."},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"ten_percent_owner":true}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":2,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"ten_percent_owner":true}},{"id":25044,"kind":"person","name":"Chen Bihua","position":3,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"ten_percent_owner":true}}],"security":"Common Shares","published_at":"2024-10-17T21:11:29.000Z","date":"2024-10-15","kind":"purchase","planned":false,"acquired":true,"shares":2700,"price":9.2624,"value":25008.48,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents the weighted average sale price of common shares purchased in a series of open market transactions on the transaction date at prices ranging from $9.26 to $9.31 per share. The Reporting Persons undertake to provide, upon request by the staff of the SEC, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of these shares were purchased by the Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\") serves as general partner of the Master Fund. Bihua Chen serves as the managing member of GP LLC and the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."}],"balance_after":801222,"source":{"system":"sec-edgar","filing":"0000929638-24-003542","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1827401/000092963824003542/form4.xml","form_type":"4"}},{"id":1385357,"issuer":{"id":5231,"kind":"organization","name":"BRIGHT MINDS BIOSCIENCES INC."},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"ten_percent_owner":true}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":2,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"ten_percent_owner":true}},{"id":25044,"kind":"person","name":"Chen Bihua","position":3,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"ten_percent_owner":true}}],"security":"Common Shares","published_at":"2024-10-17T21:11:29.000Z","date":"2024-10-15","kind":"purchase","planned":false,"acquired":true,"shares":2600,"price":8.804,"value":22890.4,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents the weighted average sale price of common shares purchased in a series of open market transactions on the transaction date at prices ranging from $8.80 to $8.905 per share. The Reporting Persons undertake to provide, upon request by the staff of the SEC, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of these shares were purchased by the Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\") serves as general partner of the Master Fund. Bihua Chen serves as the managing member of GP LLC and the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."}],"balance_after":798522,"source":{"system":"sec-edgar","filing":"0000929638-24-003542","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1827401/000092963824003542/form4.xml","form_type":"4"}},{"id":1385356,"issuer":{"id":5231,"kind":"organization","name":"BRIGHT MINDS BIOSCIENCES INC."},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"ten_percent_owner":true}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":2,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"ten_percent_owner":true}},{"id":25044,"kind":"person","name":"Chen Bihua","position":3,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"ten_percent_owner":true}}],"security":"Common Shares","published_at":"2024-10-17T21:11:29.000Z","date":"2024-10-15","kind":"purchase","planned":false,"acquired":true,"shares":8900,"price":7.3052,"value":65016.28,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents the weighted average sale price of common shares purchased in a series of open market transactions on the transaction date at prices ranging from $7.28 to $7.59 per share. The Reporting Persons undertake to provide, upon request by the staff of the SEC, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of these shares were purchased by the Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\") serves as general partner of the Master Fund. Bihua Chen serves as the managing member of GP LLC and the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."}],"balance_after":795922,"source":{"system":"sec-edgar","filing":"0000929638-24-003542","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1827401/000092963824003542/form4.xml","form_type":"4"}},{"id":1385355,"issuer":{"id":5231,"kind":"organization","name":"BRIGHT MINDS BIOSCIENCES INC."},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"ten_percent_owner":true}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":2,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"ten_percent_owner":true}},{"id":25044,"kind":"person","name":"Chen Bihua","position":3,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"ten_percent_owner":true}}],"security":"Common Shares","published_at":"2024-10-17T21:11:29.000Z","date":"2024-10-15","kind":"purchase","planned":false,"acquired":true,"shares":33343,"price":6.4247,"value":214218.7721,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sale price of common shares purchased in a series of open market transactions on the transaction date at prices ranging from $6.16 to $7.12 per share. The Reporting Persons undertake to provide, upon request by the staff of the SEC, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of these shares were purchased by the Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\") serves as general partner of the Master Fund. Bihua Chen serves as the managing member of GP LLC and the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."}],"balance_after":787022,"source":{"system":"sec-edgar","filing":"0000929638-24-003542","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1827401/000092963824003542/form4.xml","form_type":"4"}},{"id":1385354,"issuer":{"id":5231,"kind":"organization","name":"BRIGHT MINDS BIOSCIENCES INC."},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"ten_percent_owner":true}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":2,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"ten_percent_owner":true}},{"id":25044,"kind":"person","name":"Chen Bihua","position":3,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"ten_percent_owner":true}}],"security":"Common Shares","published_at":"2024-10-17T21:11:29.000Z","date":"2024-10-15","kind":"purchase","planned":false,"acquired":true,"shares":63173,"price":5.924,"value":374236.852,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price of common shares purchased in a series of open market transactions on the transaction date at prices ranging from $5.42 to $6.15 per share. The Reporting Persons undertake to provide, upon request by the staff of the SEC, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of these shares were purchased by the Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\") serves as general partner of the Master Fund. Bihua Chen serves as the managing member of GP LLC and the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."}],"balance_after":753679,"source":{"system":"sec-edgar","filing":"0000929638-24-003542","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1827401/000092963824003542/form4.xml","form_type":"4"}},{"id":1385353,"issuer":{"id":5231,"kind":"organization","name":"BRIGHT MINDS BIOSCIENCES INC."},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"ten_percent_owner":true}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":2,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"ten_percent_owner":true}},{"id":25044,"kind":"person","name":"Chen Bihua","position":3,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"ten_percent_owner":true}}],"security":"Common Shares","published_at":"2024-10-17T21:11:29.000Z","date":"2024-10-15","kind":"purchase","planned":false,"acquired":true,"shares":238097,"price":4.5304,"value":1078674.6488,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average sale price of common shares purchased in a series of open market transactions on the transaction date at prices ranging from $4.16 to $4.89 per share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission (the \"SEC\"), the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of these shares were purchased by the Master Fund (as defined below)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\") serves as general partner of the Master Fund. Bihua Chen serves as the managing member of GP LLC and the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."}],"balance_after":690506,"source":{"system":"sec-edgar","filing":"0000929638-24-003542","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1827401/000092963824003542/form4.xml","form_type":"4"}},{"id":1396780,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":25048,"kind":"organization","name":"Cormorant Private Healthcare Fund V LP","position":2,"cik":"0001969296","reported_name":"Cormorant Private Healthcare Fund V LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":25044,"kind":"person","name":"Chen Bihua","position":3,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":74741,"kind":"organization","name":"Cormorant Private Healthcare Fund IV LP","position":4,"cik":"0001871297","reported_name":"Cormorant Private Healthcare Fund IV LP","relationship":{"other":true,"other_text":"Former 10% Owner"}}],"security":"Series D Redeemable Convertible Preferred Stock","published_at":"2024-10-01T20:01:04.000Z","date":"2024-09-27","kind":"exercise","planned":false,"acquired":false,"shares":5263772,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Series D Redeemable Convertible Preferred Stock (\"Series D Preferred Stock\") automatically converted into 0.224084614 shares of Common Stock of the Issuer (\"Common Stock\") upon the closing of the Issuer's initial public offering of Common Stock.  The Series D Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Series D Redeemable Convertible Preferred Stock (\"Series D Preferred Stock\") automatically converted into 0.224084614 shares of Common Stock of the Issuer (\"Common Stock\") upon the closing of the Issuer's initial public offering of Common Stock.  The Series D Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Series D Redeemable Convertible Preferred Stock (\"Series D Preferred Stock\") automatically converted into 0.224084614 shares of Common Stock of the Issuer (\"Common Stock\") upon the closing of the Issuer's initial public offering of Common Stock.  The Series D Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Series D Redeemable Convertible Preferred Stock (\"Series D Preferred Stock\") automatically converted into 0.224084614 shares of Common Stock of the Issuer (\"Common Stock\") upon the closing of the Issuer's initial public offering of Common Stock.  The Series D Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Each share of the Series D Redeemable Convertible Preferred Stock (\"Series D Preferred Stock\") automatically converted into 0.224084614 shares of Common Stock of the Issuer (\"Common Stock\") upon the closing of the Issuer's initial public offering of Common Stock.  The Series D Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents (i) 173,704 shares of Series D Preferred Stock beneficially owned by the Master Fund (defined below), which converted into 38,924 shares of Common Stock, (ii) 2,769,271 shares of Series D Preferred Stock beneficially owned by Fund IV (defined below), which converted into 620,551 shares of Common Stock, and (iii) 2,320,797 shares of Series D Preferred Stock beneficially owned by Fund V (defined below), which converted into 520,054 shares of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"), Cormorant Private Healthcare Fund IV, LP (\"Fund IV\") and Cormorant Private Healthcare Fund V, LP (\"Fund V\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\"), Cormorant Private Healthcare GP IV, LLC (\"GP IV\") and Cormorant Private Healthcare GP V, LLC (\"GP V\") serve as General Partner of the Master Fund, Fund IV and Fund V, respectively. Bihua Chen serves as manager of Cormorant, GP LLC, GP IV  and GP V. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1179529},"source":{"system":"sec-edgar","filing":"0000929638-24-003363","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000092963824003363/form4.xml","form_type":"4"}},{"id":1396779,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":25048,"kind":"organization","name":"Cormorant Private Healthcare Fund V LP","position":2,"cik":"0001969296","reported_name":"Cormorant Private Healthcare Fund V LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":25044,"kind":"person","name":"Chen Bihua","position":3,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":74741,"kind":"organization","name":"Cormorant Private Healthcare Fund IV LP","position":4,"cik":"0001871297","reported_name":"Cormorant Private Healthcare Fund IV LP","relationship":{"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock","published_at":"2024-10-01T20:01:04.000Z","date":"2024-09-27","kind":"purchase","planned":false,"acquired":true,"shares":450000,"price":18,"value":8100000.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"), Cormorant Private Healthcare Fund IV, LP (\"Fund IV\") and Cormorant Private Healthcare Fund V, LP (\"Fund V\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\"), Cormorant Private Healthcare GP IV, LLC (\"GP IV\") and Cormorant Private Healthcare GP V, LLC (\"GP V\") serve as General Partner of the Master Fund, Fund IV and Fund V, respectively. Bihua Chen serves as manager of Cormorant, GP LLC, GP IV  and GP V. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares of Common Stock purchased for the account of the Master Fund."}],"balance_after":1629529,"source":{"system":"sec-edgar","filing":"0000929638-24-003363","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000092963824003363/form4.xml","form_type":"4"}},{"id":1396778,"issuer":{"id":5569,"kind":"organization","name":"BioAge Labs, Inc."},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":25048,"kind":"organization","name":"Cormorant Private Healthcare Fund V LP","position":2,"cik":"0001969296","reported_name":"Cormorant Private Healthcare Fund V LP","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":25044,"kind":"person","name":"Chen Bihua","position":3,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"other":true,"other_text":"Former 10% Owner"}},{"id":74741,"kind":"organization","name":"Cormorant Private Healthcare Fund IV LP","position":4,"cik":"0001871297","reported_name":"Cormorant Private Healthcare Fund IV LP","relationship":{"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock","published_at":"2024-10-01T20:01:04.000Z","date":"2024-09-27","kind":"exercise","planned":false,"acquired":true,"shares":1179529,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Series D Redeemable Convertible Preferred Stock (\"Series D Preferred Stock\") automatically converted into 0.224084614 shares of Common Stock of the Issuer (\"Common Stock\") upon the closing of the Issuer's initial public offering of Common Stock.  The Series D Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Each share of the Series D Redeemable Convertible Preferred Stock (\"Series D Preferred Stock\") automatically converted into 0.224084614 shares of Common Stock of the Issuer (\"Common Stock\") upon the closing of the Issuer's initial public offering of Common Stock.  The Series D Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents (i) 173,704 shares of Series D Preferred Stock beneficially owned by the Master Fund (defined below), which converted into 38,924 shares of Common Stock, (ii) 2,769,271 shares of Series D Preferred Stock beneficially owned by Fund IV (defined below), which converted into 620,551 shares of Common Stock, and (iii) 2,320,797 shares of Series D Preferred Stock beneficially owned by Fund V (defined below), which converted into 520,054 shares of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"), Cormorant Private Healthcare Fund IV, LP (\"Fund IV\") and Cormorant Private Healthcare Fund V, LP (\"Fund V\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\"), Cormorant Private Healthcare GP IV, LLC (\"GP IV\") and Cormorant Private Healthcare GP V, LLC (\"GP V\") serve as General Partner of the Master Fund, Fund IV and Fund V, respectively. Bihua Chen serves as manager of Cormorant, GP LLC, GP IV  and GP V. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."}],"balance_after":1179529,"source":{"system":"sec-edgar","filing":"0000929638-24-003363","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709941/000092963824003363/form4.xml","form_type":"4"}},{"id":1399919,"issuer":{"id":6261,"kind":"organization","name":"Corbus Pharmaceuticals Holdings, Inc.","symbol":"CRBP"},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"ten_percent_owner":true}},{"id":25044,"kind":"person","name":"Chen Bihua","position":2,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"ten_percent_owner":true}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":3,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-09-24T20:04:18.000Z","date":"2024-09-20","kind":"purchase","planned":false,"acquired":true,"shares":25769,"price":22.228,"value":572793.332,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents the weighted average sale price of shares of common stock purchased in a series of open market transactions on the transaction date at prices ranging from $22.00 to $22.50 per share. The Reporting Persons undertake to provide, upon request by the staff of the SEC issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of these shares were purchased by the Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\") serves as General Partner of the Master Fund. Bihua Chen serves as manager of Cormorant, GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."}],"balance_after":2375000,"source":{"system":"sec-edgar","filing":"0000929638-24-003217","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1583977/000092963824003217/form4.xml","form_type":"4"}},{"id":1399918,"issuer":{"id":6261,"kind":"organization","name":"Corbus Pharmaceuticals Holdings, Inc.","symbol":"CRBP"},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"ten_percent_owner":true}},{"id":25044,"kind":"person","name":"Chen Bihua","position":2,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"ten_percent_owner":true}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":3,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-09-24T20:04:18.000Z","date":"2024-09-20","kind":"purchase","planned":false,"acquired":true,"shares":47564,"price":21.474,"value":1021389.336,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents the weighted average sale price of shares of common stock purchased in a series of open market transactions on the transaction date at prices ranging from $21.00 to $21.99 per share. The Reporting Persons undertake to provide, upon request by the staff of the SEC issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of these shares were purchased by the Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\") serves as General Partner of the Master Fund. Bihua Chen serves as manager of Cormorant, GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."}],"balance_after":2349231,"source":{"system":"sec-edgar","filing":"0000929638-24-003217","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1583977/000092963824003217/form4.xml","form_type":"4"}},{"id":1399917,"issuer":{"id":6261,"kind":"organization","name":"Corbus Pharmaceuticals Holdings, Inc.","symbol":"CRBP"},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"ten_percent_owner":true}},{"id":25044,"kind":"person","name":"Chen Bihua","position":2,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"ten_percent_owner":true}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":3,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-09-24T20:04:18.000Z","date":"2024-09-20","kind":"purchase","planned":false,"acquired":true,"shares":139551,"price":20.418,"value":2849352.318,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents the weighted average sale price of shares of common stock purchased in a series of open market transactions on the transaction date at prices ranging from $20.00 to $20.995 per share. The Reporting Persons undertake to provide, upon request by the staff of the SEC issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of these shares were purchased by the Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\") serves as General Partner of the Master Fund. Bihua Chen serves as manager of Cormorant, GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."}],"balance_after":2301667,"source":{"system":"sec-edgar","filing":"0000929638-24-003217","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1583977/000092963824003217/form4.xml","form_type":"4"}},{"id":1399916,"issuer":{"id":6261,"kind":"organization","name":"Corbus Pharmaceuticals Holdings, Inc.","symbol":"CRBP"},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"ten_percent_owner":true}},{"id":25044,"kind":"person","name":"Chen Bihua","position":2,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"ten_percent_owner":true}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":3,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-09-24T20:04:18.000Z","date":"2024-09-20","kind":"purchase","planned":false,"acquired":true,"shares":66088,"price":19.611,"value":1296051.768,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sale price of shares of common stock purchased in a series of open market transactions on the transaction date at prices ranging from $19.00 to $19.998 per share. The Reporting Persons undertake to provide, upon request by the staff of the SEC issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of these shares were purchased by the Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\") serves as General Partner of the Master Fund. Bihua Chen serves as manager of Cormorant, GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."}],"balance_after":2162116,"source":{"system":"sec-edgar","filing":"0000929638-24-003217","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1583977/000092963824003217/form4.xml","form_type":"4"}},{"id":1399915,"issuer":{"id":6261,"kind":"organization","name":"Corbus Pharmaceuticals Holdings, Inc.","symbol":"CRBP"},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"ten_percent_owner":true}},{"id":25044,"kind":"person","name":"Chen Bihua","position":2,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"ten_percent_owner":true}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":3,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-09-24T20:04:18.000Z","date":"2024-09-20","kind":"purchase","planned":false,"acquired":true,"shares":25943,"price":18.36,"value":476313.48,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price of shares of common stock purchased in a series of open market transactions on the transaction date at prices ranging from $18.03 to $18.999 per share. The Reporting Persons undertake to provide, upon request by the staff of the SEC issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of these shares were purchased by the Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\") serves as General Partner of the Master Fund. Bihua Chen serves as manager of Cormorant, GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."}],"balance_after":2096028,"source":{"system":"sec-edgar","filing":"0000929638-24-003217","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1583977/000092963824003217/form4.xml","form_type":"4"}},{"id":1399914,"issuer":{"id":6261,"kind":"organization","name":"Corbus Pharmaceuticals Holdings, Inc.","symbol":"CRBP"},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"ten_percent_owner":true}},{"id":25044,"kind":"person","name":"Chen Bihua","position":2,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"ten_percent_owner":true}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":3,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-09-24T20:04:18.000Z","date":"2024-09-20","kind":"purchase","planned":false,"acquired":true,"shares":45085,"price":17.475,"value":787860.375,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average sale price of shares of common stock purchased in a series of open market transactions on the transaction date at prices ranging from $17.00 to $17.95 per share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission (the \"SEC\"), the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of these shares were purchased by the Master Fund (as defined below)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\") serves as General Partner of the Master Fund. Bihua Chen serves as manager of Cormorant, GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."}],"balance_after":2070085,"source":{"system":"sec-edgar","filing":"0000929638-24-003217","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583977/000092963824003217/form4.xml","form_type":"4"}},{"id":1480847,"issuer":{"id":6606,"kind":"organization","name":"Biomea Fusion, Inc."},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"director":true,"ten_percent_owner":true}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":2,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"ten_percent_owner":true}},{"id":25047,"kind":"organization","name":"Cormorant Private Healthcare Fund III LP","position":3,"cik":"0001817320","reported_name":"Cormorant Private Healthcare Fund III LP","relationship":{"ten_percent_owner":true}},{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":4,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"ten_percent_owner":true}}],"security":"Stock Option (right to buy)","published_at":"2024-06-13T20:38:16.000Z","date":"2024-06-12","kind":"grant","planned":false,"acquired":true,"shares":51025,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The options vest in full upon the earlier of (i) the one-year anniversary of the date of grant or (ii) immediately prior to the annual meeting of the Issuer's stockholders that occurs following the date of grant, subject to Ms. Chen's continuing service to the Issuer through such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Stock options granted to Bihua Chen, in her capacity as a director of the Issuer."}],"balance_after":51.025,"derivative":{"exercise_price":4.63,"expiration_date":"2034-06-11","underlying":"Common Stock","underlying_shares":51025},"source":{"system":"sec-edgar","filing":"0000929638-24-002175","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1817320/000092963824002175/form4.xml","form_type":"4"}},{"id":1523098,"issuer":{"id":5702,"kind":"organization","name":"EyePoint, Inc."},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"ten_percent_owner":true}},{"id":25044,"kind":"person","name":"Chen Bihua","position":2,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"ten_percent_owner":true}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":3,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-05-08T20:23:14.000Z","date":"2024-05-06","kind":"purchase","planned":false,"acquired":true,"shares":207153,"price":12.36,"value":2560411.08,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale right of the shares purchased in a series of open market transactions on the transaction date at prices ranging from $12.08 to $12.95 per share. The Reporting Persons undertake to provide, upon request by the staff of the SEC, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of the shares reported herein were purchased by the Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\") serves as General Partner of the Master Fund. Bihua Chen serves as manager of Cormorant, GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."}],"balance_after":8325000,"source":{"system":"sec-edgar","filing":"0000929638-24-001743","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1314102/000092963824001743/form4.xml","form_type":"4"}},{"id":1523097,"issuer":{"id":5702,"kind":"organization","name":"EyePoint, Inc."},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"ten_percent_owner":true}},{"id":25044,"kind":"person","name":"Chen Bihua","position":2,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"ten_percent_owner":true}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":3,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-05-08T20:23:14.000Z","date":"2024-05-06","kind":"purchase","planned":false,"acquired":true,"shares":642847,"price":11.7,"value":7521309.9,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of Common Stock (the \"shares\") purchased in a series of open market transactions on the transaction date at prices ranging from $11.08 to $12.07 per share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission (the \"SEC\"), the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of the shares reported herein were purchased by the Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\") serves as General Partner of the Master Fund. Bihua Chen serves as manager of Cormorant, GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."}],"balance_after":8117847,"source":{"system":"sec-edgar","filing":"0000929638-24-001743","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314102/000092963824001743/form4.xml","form_type":"4"}},{"id":1537475,"issuer":{"id":5702,"kind":"organization","name":"EyePoint, Inc."},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"ten_percent_owner":true}},{"id":25044,"kind":"person","name":"Chen Bihua","position":2,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"ten_percent_owner":true}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":3,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-04-22T20:00:41.000Z","date":"2024-04-18","kind":"purchase","planned":false,"acquired":true,"shares":186521,"price":18.9,"value":3525246.9,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale right of the shares purchased in a series of open market transactions on the transaction date at prices ranging from $18.43 to $19.06 per share. The Reporting Persons undertake to provide, upon request by the staff of the SEC, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of the shares reported herein were purchased by the Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\") serves as General Partner of the Master Fund. Bihua Chen serves as manager of Cormorant, GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."}],"balance_after":7475000,"source":{"system":"sec-edgar","filing":"0000929638-24-001536","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1314102/000092963824001536/form4.xml","form_type":"4"}},{"id":1537474,"issuer":{"id":5702,"kind":"organization","name":"EyePoint, Inc."},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"ten_percent_owner":true}},{"id":25044,"kind":"person","name":"Chen Bihua","position":2,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"ten_percent_owner":true}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":3,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-04-22T20:00:41.000Z","date":"2024-04-18","kind":"purchase","planned":false,"acquired":true,"shares":395244,"price":17.62,"value":6964199.28,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of Common Stock (the \"shares\") purchased in a series of open market transactions on the transaction date at prices ranging from $17.36 to $18.25 per share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission (the \"SEC\"), the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of the shares reported herein were purchased by the Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\") serves as General Partner of the Master Fund. Bihua Chen serves as manager of Cormorant, GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."}],"balance_after":7288479,"source":{"system":"sec-edgar","filing":"0000929638-24-001536","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314102/000092963824001536/form4.xml","form_type":"4"}},{"id":1549987,"issuer":{"id":5884,"kind":"organization","name":"Immuneering Corp"},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"ten_percent_owner":true}},{"id":25044,"kind":"person","name":"Chen Bihua","position":2,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"ten_percent_owner":true}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":3,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"ten_percent_owner":true}},{"id":25047,"kind":"organization","name":"Cormorant Private Healthcare Fund III LP","position":4,"cik":"0001817320","reported_name":"Cormorant Private Healthcare Fund III LP","relationship":{"ten_percent_owner":true}}],"security":"Class A Common Stock","published_at":"2024-04-03T21:37:04.000Z","date":"2024-04-01","kind":"sale","planned":false,"acquired":false,"shares":398600,"price":2.9,"value":1155940.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\") and Cormorant Private Healthcare Fund III, LP (\"Fund III\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\") and Cormorant Private Healthcare GP III, LLC (\"GP III\") serve as General Partner of the Master Fund and Fund III, respectively. Bihua Chen serves as manager of Cormorant, GP LLC and GP III. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"Represents (i) 955,689 shares of Class A Common Stock beneficially owned by the Master Fund and (ii) 1,939,584 shares of Class A Common Stock beneficially owned by Fund III."}],"balance_after":2895273,"source":{"system":"sec-edgar","filing":"0000929638-24-001336","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1817320/000092963824001336/form4.xml","form_type":"4"}},{"id":1549986,"issuer":{"id":5884,"kind":"organization","name":"Immuneering Corp"},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"ten_percent_owner":true}},{"id":25044,"kind":"person","name":"Chen Bihua","position":2,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"ten_percent_owner":true}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":3,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"ten_percent_owner":true}},{"id":25047,"kind":"organization","name":"Cormorant Private Healthcare Fund III LP","position":4,"cik":"0001817320","reported_name":"Cormorant Private Healthcare Fund III LP","relationship":{"ten_percent_owner":true}}],"security":"Class A Common Stock","published_at":"2024-04-03T21:37:04.000Z","date":"2024-04-01","kind":"sale","planned":false,"acquired":false,"shares":280,"price":2.97,"value":831.6,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\") and Cormorant Private Healthcare Fund III, LP (\"Fund III\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\") and Cormorant Private Healthcare GP III, LLC (\"GP III\") serve as General Partner of the Master Fund and Fund III, respectively. Bihua Chen serves as manager of Cormorant, GP LLC and GP III. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Represents (i) 1,086,227 shares of Class A Common Stock beneficially owned by the Master Fund and (ii) 2,206,646 shares of Class A Common Stock beneficially owned by Fund III."}],"balance_after":3293873,"source":{"system":"sec-edgar","filing":"0000929638-24-001336","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1817320/000092963824001336/form4.xml","form_type":"4"}},{"id":1549985,"issuer":{"id":5884,"kind":"organization","name":"Immuneering Corp"},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"ten_percent_owner":true}},{"id":25044,"kind":"person","name":"Chen Bihua","position":2,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"ten_percent_owner":true}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":3,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"ten_percent_owner":true}},{"id":25047,"kind":"organization","name":"Cormorant Private Healthcare Fund III LP","position":4,"cik":"0001817320","reported_name":"Cormorant Private Healthcare Fund III LP","relationship":{"ten_percent_owner":true}}],"security":"Class A Common Stock","published_at":"2024-04-03T21:37:04.000Z","date":"2024-04-01","kind":"sale","planned":false,"acquired":false,"shares":10,"price":2.98,"value":29.8,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\") and Cormorant Private Healthcare Fund III, LP (\"Fund III\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\") and Cormorant Private Healthcare GP III, LLC (\"GP III\") serve as General Partner of the Master Fund and Fund III, respectively. Bihua Chen serves as manager of Cormorant, GP LLC and GP III. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Represents (i) 1,087,319 shares of Class A Common Stock beneficially owned by the Master Fund and (ii) 2,206,834 shares of Class A Common Stock beneficially owned by Fund III."}],"balance_after":3294153,"source":{"system":"sec-edgar","filing":"0000929638-24-001336","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1817320/000092963824001336/form4.xml","form_type":"4"}},{"id":1549984,"issuer":{"id":5884,"kind":"organization","name":"Immuneering Corp"},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"ten_percent_owner":true}},{"id":25044,"kind":"person","name":"Chen Bihua","position":2,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"ten_percent_owner":true}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":3,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"ten_percent_owner":true}},{"id":25047,"kind":"organization","name":"Cormorant Private Healthcare Fund III LP","position":4,"cik":"0001817320","reported_name":"Cormorant Private Healthcare Fund III LP","relationship":{"ten_percent_owner":true}}],"security":"Class A Common Stock","published_at":"2024-04-03T21:37:04.000Z","date":"2024-04-01","kind":"sale","planned":false,"acquired":false,"shares":10,"price":3.01,"value":30.1,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\") and Cormorant Private Healthcare Fund III, LP (\"Fund III\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\") and Cormorant Private Healthcare GP III, LLC (\"GP III\") serve as General Partner of the Master Fund and Fund III, respectively. Bihua Chen serves as manager of Cormorant, GP LLC and GP III. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Represents (i) 1,087,322 shares of Class A Common Stock beneficially owned by the Master Fund and (ii) 2,206,841 shares of Class A Common Stock beneficially owned by Fund III."}],"balance_after":3294163,"source":{"system":"sec-edgar","filing":"0000929638-24-001336","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1817320/000092963824001336/form4.xml","form_type":"4"}},{"id":1549983,"issuer":{"id":5884,"kind":"organization","name":"Immuneering Corp"},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"ten_percent_owner":true}},{"id":25044,"kind":"person","name":"Chen Bihua","position":2,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"ten_percent_owner":true}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":3,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"ten_percent_owner":true}},{"id":25047,"kind":"organization","name":"Cormorant Private Healthcare Fund III LP","position":4,"cik":"0001817320","reported_name":"Cormorant Private Healthcare Fund III LP","relationship":{"ten_percent_owner":true}}],"security":"Class A Common Stock","published_at":"2024-04-03T21:37:04.000Z","date":"2024-04-01","kind":"sale","planned":false,"acquired":false,"shares":600,"price":3.03,"value":1818.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\") and Cormorant Private Healthcare Fund III, LP (\"Fund III\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\") and Cormorant Private Healthcare GP III, LLC (\"GP III\") serve as General Partner of the Master Fund and Fund III, respectively. Bihua Chen serves as manager of Cormorant, GP LLC and GP III. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Represents (i) 1,087,325 shares of Class A Common Stock beneficially owned by the Master Fund and (ii) 2,206,848 shares of Class A Common Stock beneficially owned by Fund III."}],"balance_after":3294173,"source":{"system":"sec-edgar","filing":"0000929638-24-001336","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1817320/000092963824001336/form4.xml","form_type":"4"}},{"id":1549982,"issuer":{"id":5884,"kind":"organization","name":"Immuneering Corp"},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"ten_percent_owner":true}},{"id":25044,"kind":"person","name":"Chen Bihua","position":2,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"ten_percent_owner":true}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":3,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"ten_percent_owner":true}},{"id":25047,"kind":"organization","name":"Cormorant Private Healthcare Fund III LP","position":4,"cik":"0001817320","reported_name":"Cormorant Private Healthcare Fund III LP","relationship":{"ten_percent_owner":true}}],"security":"Class A Common Stock","published_at":"2024-04-03T21:37:04.000Z","date":"2024-04-01","kind":"sale","planned":false,"acquired":false,"shares":100,"price":3.05,"value":305.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\") and Cormorant Private Healthcare Fund III, LP (\"Fund III\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\") and Cormorant Private Healthcare GP III, LLC (\"GP III\") serve as General Partner of the Master Fund and Fund III, respectively. Bihua Chen serves as manager of Cormorant, GP LLC and GP III. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents (i) 1,087,523 shares of Class A Common Stock beneficially owned by the Master Fund and (ii) 2,207,250 shares of Class A Common Stock beneficially owned by Fund III."}],"balance_after":3294773,"source":{"system":"sec-edgar","filing":"0000929638-24-001336","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817320/000092963824001336/form4.xml","form_type":"4"}},{"id":1549981,"issuer":{"id":5884,"kind":"organization","name":"Immuneering Corp"},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"ten_percent_owner":true}},{"id":25044,"kind":"person","name":"Chen Bihua","position":2,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"ten_percent_owner":true}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":3,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"ten_percent_owner":true}},{"id":25047,"kind":"organization","name":"Cormorant Private Healthcare Fund III LP","position":4,"cik":"0001817320","reported_name":"Cormorant Private Healthcare Fund III LP","relationship":{"ten_percent_owner":true}}],"security":"Class A Common Stock","published_at":"2024-04-03T21:37:04.000Z","date":"2024-04-01","kind":"sale","planned":false,"acquired":false,"shares":300,"price":3.065,"value":919.5,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\") and Cormorant Private Healthcare Fund III, LP (\"Fund III\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\") and Cormorant Private Healthcare GP III, LLC (\"GP III\") serve as General Partner of the Master Fund and Fund III, respectively. Bihua Chen serves as manager of Cormorant, GP LLC and GP III. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents (i) 1,087,556 shares of Class A Common Stock beneficially owned by the Master Fund and (ii) 2,207,317 shares of Class A Common Stock beneficially owned by Fund III."}],"balance_after":3294873,"source":{"system":"sec-edgar","filing":"0000929638-24-001336","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817320/000092963824001336/form4.xml","form_type":"4"}},{"id":1549980,"issuer":{"id":5884,"kind":"organization","name":"Immuneering Corp"},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"ten_percent_owner":true}},{"id":25044,"kind":"person","name":"Chen Bihua","position":2,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"ten_percent_owner":true}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":3,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"ten_percent_owner":true}},{"id":25047,"kind":"organization","name":"Cormorant Private Healthcare Fund III LP","position":4,"cik":"0001817320","reported_name":"Cormorant Private Healthcare Fund III LP","relationship":{"ten_percent_owner":true}}],"security":"Class A Common Stock","published_at":"2024-04-03T21:37:04.000Z","date":"2024-04-01","kind":"sale","planned":false,"acquired":false,"shares":100,"price":3.07,"value":307.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\") and Cormorant Private Healthcare Fund III, LP (\"Fund III\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\") and Cormorant Private Healthcare GP III, LLC (\"GP III\") serve as General Partner of the Master Fund and Fund III, respectively. Bihua Chen serves as manager of Cormorant, GP LLC and GP III. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents (i) 1,087,655 shares of Class A Common Stock beneficially owned by the Master Fund and (ii) 2,207,518 shares of Class A Common Stock beneficially owned by Fund III."}],"balance_after":3295173,"source":{"system":"sec-edgar","filing":"0000929638-24-001336","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817320/000092963824001336/form4.xml","form_type":"4"}},{"id":1572574,"issuer":{"id":5884,"kind":"organization","name":"Immuneering Corp"},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"ten_percent_owner":true}},{"id":25044,"kind":"person","name":"Chen Bihua","position":2,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"ten_percent_owner":true}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":3,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"ten_percent_owner":true}},{"id":25047,"kind":"organization","name":"Cormorant Private Healthcare Fund III LP","position":4,"cik":"0001817320","reported_name":"Cormorant Private Healthcare Fund III LP","relationship":{"ten_percent_owner":true}}],"security":"Class A Common Stock","published_at":"2024-03-18T21:59:40.000Z","date":"2024-03-15","kind":"sale","planned":false,"acquired":false,"shares":400000,"price":2.141,"value":856400.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Represents the weighted average sale price of shares of Class A Common Stock sold in a series of open market transactions on the transaction date at prices ranging from $1.90 to $2.82 per share. The Reporting Persons undertake to provide, upon request by the staff of the SEC issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price. All of these shares were sold by the Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\") and Cormorant Private Healthcare Fund III, LP (\"Fund III\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\") and Cormorant Private Healthcare GP III, LLC (\"GP III\") serve as General Partner of the Master Fund and Fund III, respectively. Bihua Chen serves as manager of Cormorant, GP LLC and GP III. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"Represents (i) 1,087,688 shares of Class A Common Stock beneficially owned by the Master Fund and (ii) 2,207,585 shares of Class A Common Stock beneficially owned by Fund III."}],"balance_after":3295273,"source":{"system":"sec-edgar","filing":"0000929638-24-001046","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1817320/000092963824001046/form4.xml","form_type":"4"}},{"id":1572573,"issuer":{"id":5884,"kind":"organization","name":"Immuneering Corp"},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"ten_percent_owner":true}},{"id":25044,"kind":"person","name":"Chen Bihua","position":2,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"ten_percent_owner":true}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":3,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"ten_percent_owner":true}},{"id":25047,"kind":"organization","name":"Cormorant Private Healthcare Fund III LP","position":4,"cik":"0001817320","reported_name":"Cormorant Private Healthcare Fund III LP","relationship":{"ten_percent_owner":true}}],"security":"Class A Common Stock","published_at":"2024-03-18T21:59:40.000Z","date":"2024-03-14","kind":"sale","planned":false,"acquired":false,"shares":11040,"price":5.968,"value":65886.72,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Represents the weighted average sale price of shares of Class A Common Stock sold in a series of open market transactions on the transaction date at prices ranging from $5.90 to $6.18 per share. The Reporting Persons undertake to provide, upon request by the staff of the SEC issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price. All of these shares were sold by the Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\") and Cormorant Private Healthcare Fund III, LP (\"Fund III\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\") and Cormorant Private Healthcare GP III, LLC (\"GP III\") serve as General Partner of the Master Fund and Fund III, respectively. Bihua Chen serves as manager of Cormorant, GP LLC and GP III. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"Represents (i) 1,487,688 shares of Class A Common Stock beneficially owned by the Master Fund and (ii) 2,207,585 shares of Class A Common Stock beneficially owned by Fund III."}],"balance_after":3695273,"source":{"system":"sec-edgar","filing":"0000929638-24-001046","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1817320/000092963824001046/form4.xml","form_type":"4"}},{"id":1572572,"issuer":{"id":5884,"kind":"organization","name":"Immuneering Corp"},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"ten_percent_owner":true}},{"id":25044,"kind":"person","name":"Chen Bihua","position":2,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"ten_percent_owner":true}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":3,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"ten_percent_owner":true}},{"id":25047,"kind":"organization","name":"Cormorant Private Healthcare Fund III LP","position":4,"cik":"0001817320","reported_name":"Cormorant Private Healthcare Fund III LP","relationship":{"ten_percent_owner":true}}],"security":"Class A Common Stock","published_at":"2024-03-18T21:59:40.000Z","date":"2024-03-14","kind":"sale","planned":false,"acquired":false,"shares":54215,"price":5.374,"value":291351.41,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents the weighted average sale price of shares of Class A Common Stock sold in a series of open market transactions on the transaction date at prices ranging from $4.90 to $5.89 per share. The Reporting Persons undertake to provide, upon request by the staff of the SEC issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price. All of these shares were sold by the Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\") and Cormorant Private Healthcare Fund III, LP (\"Fund III\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\") and Cormorant Private Healthcare GP III, LLC (\"GP III\") serve as General Partner of the Master Fund and Fund III, respectively. Bihua Chen serves as manager of Cormorant, GP LLC and GP III. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Represents (i) 1,498,728 shares of Class A Common Stock beneficially owned by the Master Fund and (ii) 2,207,585 shares of Class A Common Stock beneficially owned by Fund III."}],"balance_after":3706313,"source":{"system":"sec-edgar","filing":"0000929638-24-001046","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817320/000092963824001046/form4.xml","form_type":"4"}},{"id":1572571,"issuer":{"id":5884,"kind":"organization","name":"Immuneering Corp"},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"ten_percent_owner":true}},{"id":25044,"kind":"person","name":"Chen Bihua","position":2,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"ten_percent_owner":true}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":3,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"ten_percent_owner":true}},{"id":25047,"kind":"organization","name":"Cormorant Private Healthcare Fund III LP","position":4,"cik":"0001817320","reported_name":"Cormorant Private Healthcare Fund III LP","relationship":{"ten_percent_owner":true}}],"security":"Class A Common Stock","published_at":"2024-03-18T21:59:40.000Z","date":"2024-03-14","kind":"sale","planned":false,"acquired":false,"shares":98570,"price":4.245,"value":418429.65,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sale price of shares of Class A Common Stock sold in a series of open market transactions on the transaction date at prices ranging from $3.90 to $4.895 per share. The Reporting Persons undertake to provide, upon request by the staff of the SEC issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price. All of these shares were sold by the Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\") and Cormorant Private Healthcare Fund III, LP (\"Fund III\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\") and Cormorant Private Healthcare GP III, LLC (\"GP III\") serve as General Partner of the Master Fund and Fund III, respectively. Bihua Chen serves as manager of Cormorant, GP LLC and GP III. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Represents (i) 1,552,943 shares of Class A Common Stock beneficially owned by the Master Fund and (ii) 2,207,585 shares of Class A Common Stock beneficially owned by Fund III."}],"balance_after":3760528,"source":{"system":"sec-edgar","filing":"0000929638-24-001046","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817320/000092963824001046/form4.xml","form_type":"4"}},{"id":1572570,"issuer":{"id":5884,"kind":"organization","name":"Immuneering Corp"},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"ten_percent_owner":true}},{"id":25044,"kind":"person","name":"Chen Bihua","position":2,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"ten_percent_owner":true}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":3,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"ten_percent_owner":true}},{"id":25047,"kind":"organization","name":"Cormorant Private Healthcare Fund III LP","position":4,"cik":"0001817320","reported_name":"Cormorant Private Healthcare Fund III LP","relationship":{"ten_percent_owner":true}}],"security":"Class A Common Stock","published_at":"2024-03-18T21:59:40.000Z","date":"2024-03-14","kind":"sale","planned":false,"acquired":false,"shares":345266,"price":3.235,"value":1116935.51,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average sale price of shares of Class A Common Stock sold in a series of open market transactions on the transaction date at prices ranging from $2.90 to $3.895 per share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission (the \"SEC\"), the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price. All of these shares were sold by the Master Fund (as defined below)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\") and Cormorant Private Healthcare Fund III, LP (\"Fund III\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\") and Cormorant Private Healthcare GP III, LLC (\"GP III\") serve as General Partner of the Master Fund and Fund III, respectively. Bihua Chen serves as manager of Cormorant, GP LLC and GP III. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents (i) 1,651,513 shares of Class A Common Stock beneficially owned by the Master Fund and (ii) 2,207,585 shares of Class A Common Stock beneficially owned by Fund III."}],"balance_after":3859098,"source":{"system":"sec-edgar","filing":"0000929638-24-001046","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817320/000092963824001046/form4.xml","form_type":"4"}},{"id":1583578,"issuer":{"id":6261,"kind":"organization","name":"Corbus Pharmaceuticals Holdings, Inc.","symbol":"CRBP"},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"ten_percent_owner":true}},{"id":25044,"kind":"person","name":"Chen Bihua","position":2,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"ten_percent_owner":true}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":3,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-03-11T21:34:06.000Z","date":"2024-03-08","kind":"purchase","planned":false,"acquired":true,"shares":8862,"price":45.96,"value":407297.52,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F11","text":"Represents the weighted average sale price of shares of common stock purchased in a series of open market transactions on the transaction date at prices ranging from $45.88 to $46.00 per share. The Reporting Persons undertake to provide, upon request by the staff of the SEC issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of these shares were purchased by the Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\") serves as General Partner of the Master Fund. Bihua Chen serves as manager of Cormorant, GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."}],"balance_after":2025000,"source":{"system":"sec-edgar","filing":"0000929638-24-000985","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1583977/000092963824000985/form4.xml","form_type":"4"}},{"id":1583577,"issuer":{"id":6261,"kind":"organization","name":"Corbus Pharmaceuticals Holdings, Inc.","symbol":"CRBP"},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"ten_percent_owner":true}},{"id":25044,"kind":"person","name":"Chen Bihua","position":2,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"ten_percent_owner":true}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":3,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-03-11T21:34:06.000Z","date":"2024-03-08","kind":"purchase","planned":false,"acquired":true,"shares":156597,"price":45.26,"value":7087580.22,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Represents the weighted average sale price of shares of common stock purchased in a series of open market transactions on the transaction date at prices ranging from $44.84 to $45.72 per share. The Reporting Persons undertake to provide, upon request by the staff of the SEC issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of these shares were purchased by the Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\") serves as General Partner of the Master Fund. Bihua Chen serves as manager of Cormorant, GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."}],"balance_after":2016138,"source":{"system":"sec-edgar","filing":"0000929638-24-000985","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1583977/000092963824000985/form4.xml","form_type":"4"}},{"id":1583576,"issuer":{"id":6261,"kind":"organization","name":"Corbus Pharmaceuticals Holdings, Inc.","symbol":"CRBP"},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"ten_percent_owner":true}},{"id":25044,"kind":"person","name":"Chen Bihua","position":2,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"ten_percent_owner":true}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":3,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-03-11T21:34:06.000Z","date":"2024-03-08","kind":"purchase","planned":false,"acquired":true,"shares":61668,"price":44.62,"value":2751626.16,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Represents the weighted average sale price of shares of common stock purchased in a series of open market transactions on the transaction date at prices ranging from $44.20 to $44.82 per share. The Reporting Persons undertake to provide, upon request by the staff of the SEC issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of these shares were purchased by the Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\") serves as General Partner of the Master Fund. Bihua Chen serves as manager of Cormorant, GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."}],"balance_after":1859541,"source":{"system":"sec-edgar","filing":"0000929638-24-000985","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1583977/000092963824000985/form4.xml","form_type":"4"}},{"id":1583575,"issuer":{"id":6261,"kind":"organization","name":"Corbus Pharmaceuticals Holdings, Inc.","symbol":"CRBP"},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"ten_percent_owner":true}},{"id":25044,"kind":"person","name":"Chen Bihua","position":2,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"ten_percent_owner":true}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":3,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-03-11T21:34:06.000Z","date":"2024-03-08","kind":"purchase","planned":false,"acquired":true,"shares":18548,"price":43.26,"value":802386.48,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Represents the weighted average sale price of shares of common stock purchased in a series of open market transactions on the transaction date at prices ranging from $43.15 to $43.82 per share. The Reporting Persons undertake to provide, upon request by the staff of the SEC issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of these shares were purchased by the Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\") serves as General Partner of the Master Fund. Bihua Chen serves as manager of Cormorant, GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."}],"balance_after":1797873,"source":{"system":"sec-edgar","filing":"0000929638-24-000985","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1583977/000092963824000985/form4.xml","form_type":"4"}},{"id":1583574,"issuer":{"id":6261,"kind":"organization","name":"Corbus Pharmaceuticals Holdings, Inc.","symbol":"CRBP"},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"ten_percent_owner":true}},{"id":25044,"kind":"person","name":"Chen Bihua","position":2,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"ten_percent_owner":true}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":3,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-03-11T21:34:06.000Z","date":"2024-03-08","kind":"purchase","planned":false,"acquired":true,"shares":24983,"price":42.25,"value":1055531.75,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents the weighted average sale price of shares of common stock purchased in a series of open market transactions on the transaction date at prices ranging from $42.24 to $42.48 per share. The Reporting Persons undertake to provide, upon request by the staff of the SEC issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of these shares were purchased by the Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\") serves as General Partner of the Master Fund. Bihua Chen serves as manager of Cormorant, GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."}],"balance_after":1779325,"source":{"system":"sec-edgar","filing":"0000929638-24-000985","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1583977/000092963824000985/form4.xml","form_type":"4"}},{"id":1583573,"issuer":{"id":6261,"kind":"organization","name":"Corbus Pharmaceuticals Holdings, Inc.","symbol":"CRBP"},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"ten_percent_owner":true}},{"id":25044,"kind":"person","name":"Chen Bihua","position":2,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"ten_percent_owner":true}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":3,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-03-11T21:34:06.000Z","date":"2024-03-08","kind":"purchase","planned":false,"acquired":true,"shares":29342,"price":41.23,"value":1209770.66,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents the weighted average sale price of shares of common stock purchased in a series of open market transactions on the transaction date at prices ranging from $40.83 to $41.50 per share. The Reporting Persons undertake to provide, upon request by the staff of the SEC issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of these shares were purchased by the Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\") serves as General Partner of the Master Fund. Bihua Chen serves as manager of Cormorant, GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."}],"balance_after":1754342,"source":{"system":"sec-edgar","filing":"0000929638-24-000985","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1583977/000092963824000985/form4.xml","form_type":"4"}},{"id":1583572,"issuer":{"id":6261,"kind":"organization","name":"Corbus Pharmaceuticals Holdings, Inc.","symbol":"CRBP"},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"ten_percent_owner":true}},{"id":25044,"kind":"person","name":"Chen Bihua","position":2,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"ten_percent_owner":true}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":3,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-03-11T21:34:06.000Z","date":"2024-03-07","kind":"purchase","planned":false,"acquired":true,"shares":102140,"price":41.23,"value":4211232.2,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents the weighted average sale price of shares of common stock purchased in a series of open market transactions on the transaction date at prices ranging from $40.53 to $41.50 per share. The Reporting Persons undertake to provide, upon request by the staff of the SEC issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of these shares were purchased by the Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\") serves as General Partner of the Master Fund. Bihua Chen serves as manager of Cormorant, GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."}],"balance_after":1725000,"source":{"system":"sec-edgar","filing":"0000929638-24-000985","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1583977/000092963824000985/form4.xml","form_type":"4"}},{"id":1583571,"issuer":{"id":6261,"kind":"organization","name":"Corbus Pharmaceuticals Holdings, Inc.","symbol":"CRBP"},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"ten_percent_owner":true}},{"id":25044,"kind":"person","name":"Chen Bihua","position":2,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"ten_percent_owner":true}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":3,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-03-11T21:34:06.000Z","date":"2024-03-07","kind":"purchase","planned":false,"acquired":true,"shares":90325,"price":39.99,"value":3612096.75,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sale price of shares of common stock purchased in a series of open market transactions on the transaction date at prices ranging from $39.55 to $40.50 per share. The Reporting Persons undertake to provide, upon request by the staff of the SEC issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of these shares were purchased by the Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\") serves as General Partner of the Master Fund. Bihua Chen serves as manager of Cormorant, GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."}],"balance_after":1622860,"source":{"system":"sec-edgar","filing":"0000929638-24-000985","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1583977/000092963824000985/form4.xml","form_type":"4"}},{"id":1583570,"issuer":{"id":6261,"kind":"organization","name":"Corbus Pharmaceuticals Holdings, Inc.","symbol":"CRBP"},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"ten_percent_owner":true}},{"id":25044,"kind":"person","name":"Chen Bihua","position":2,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"ten_percent_owner":true}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":3,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-03-11T21:34:06.000Z","date":"2024-03-07","kind":"purchase","planned":false,"acquired":true,"shares":10736,"price":39.13,"value":420099.68,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price of shares of common stock purchased in a series of open market transactions on the transaction date at prices ranging from $38.77 to $39.53 per share. The Reporting Persons undertake to provide, upon request by the staff of the SEC issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of these shares were purchased by the Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\") serves as General Partner of the Master Fund. Bihua Chen serves as manager of Cormorant, GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."}],"balance_after":1532535,"source":{"system":"sec-edgar","filing":"0000929638-24-000985","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1583977/000092963824000985/form4.xml","form_type":"4"}},{"id":1583569,"issuer":{"id":6261,"kind":"organization","name":"Corbus Pharmaceuticals Holdings, Inc.","symbol":"CRBP"},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"ten_percent_owner":true}},{"id":25044,"kind":"person","name":"Chen Bihua","position":2,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"ten_percent_owner":true}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":3,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-03-11T21:34:06.000Z","date":"2024-03-07","kind":"purchase","planned":false,"acquired":true,"shares":46799,"price":37.82,"value":1769938.18,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average sale price of shares of common stock purchased in a series of open market transactions on the transaction date at prices ranging from $37.53 to $38.00 per share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission (the \"SEC\"), the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of these shares were purchased by the Master Fund (as defined below)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\") serves as General Partner of the Master Fund. Bihua Chen serves as manager of Cormorant, GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."}],"balance_after":1521799,"source":{"system":"sec-edgar","filing":"0000929638-24-000985","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583977/000092963824000985/form4.xml","form_type":"4"}},{"id":1646543,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO and Chairperson"}}],"security":"Class A Ordinary Shares","published_at":"2024-02-14T00:48:00.000Z","date":"2024-02-13","kind":"purchase","planned":false,"acquired":true,"shares":903600,"price":10,"value":9036000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Cormorant Private Healthcare Fund V, LP is the record holder of such securities. Ms. Chen is the managing member of Cormorant Private Healthcare Fund V, LP and has voting and investment discretion with respect to the ordinary shares of record held thereby. Ms. Chen disclaims any beneficial ownership of the securities held by Cormorant Private Healthcare Fund V, LP other than to the extent of any pecuniary interest she may have therein, directly or indirectly."}],"balance_after":903600,"source":{"system":"sec-edgar","filing":"0001213900-24-013534","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000121390024013534/ownership.xml","form_type":"4"}},{"id":1646542,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO and Chairperson"}}],"security":"Class A Ordinary Shares","published_at":"2024-02-14T00:48:00.000Z","date":"2024-02-13","kind":"purchase","planned":false,"acquired":true,"shares":1427040,"price":10,"value":14270400.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Cormorant Private Healthcare Fund III, LP is the record holder of such securities. Ms. Chen is the managing member of Cormorant Private Healthcare Fund III, LP and has voting and investment discretion with respect to the ordinary shares of record held thereby. Ms. Chen disclaims any beneficial ownership of the securities held by Cormorant Private Healthcare Fund III, LP other than to the extent of any pecuniary interest she may have therein, directly or indirectly."}],"balance_after":1427040,"source":{"system":"sec-edgar","filing":"0001213900-24-013534","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000121390024013534/ownership.xml","form_type":"4"}},{"id":1646541,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO and Chairperson"}}],"security":"Class A Ordinary Shares","published_at":"2024-02-14T00:48:00.000Z","date":"2024-02-13","kind":"purchase","planned":false,"acquired":true,"shares":69360,"price":10,"value":693600.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Cormorant Global Healthcare Master Fund LP is the record holder of such securities. Ms. Chen is the managing member of Cormorant Global Healthcare Master Fund LP and has voting and investment discretion with respect to the ordinary shares of record held thereby. Ms. Chen disclaims any beneficial ownership of the securities held by Cormorant Global Healthcare Master Fund LP other than to the extent of any pecuniary interest she may have therein, directly or indirectly."}],"balance_after":69360,"source":{"system":"sec-edgar","filing":"0001213900-24-013534","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000121390024013534/ownership.xml","form_type":"4"}},{"id":1646540,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO and Chairperson"}}],"security":"Class A Ordinary Shares","published_at":"2024-02-14T00:48:00.000Z","date":"2024-02-13","kind":"grant","planned":false,"acquired":true,"shares":509000,"price":10,"value":5090000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Helix Holdings II LLC is the record holder of such securities. Cormorant Private Healthcare Fund III, LP, a Delaware limited partnership, Cormorant Private Healthcare Fund V, LP, a Delaware limited partnership, and Cormorant Global Healthcare Master Fund, LP, a Cayman Islands limited partnership, are the members of Helix Holdings II LLC. Bihua Chen is the manager of Helix Holdings II LLC and is the managing member of each of the three members of Helix Holdings II LLC and has voting and investment discretion with respect to the ordinary shares held of record by Helix Holdings II LLC. Ms. Chen disclaims any beneficial ownership of the securities held by Helix Holdings II LLC other than to the extent of any pecuniary interest she may have therein, directly or indirectly."}],"balance_after":509000,"source":{"system":"sec-edgar","filing":"0001213900-24-013534","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000121390024013534/ownership.xml","form_type":"4"}},{"id":1656484,"issuer":{"id":6261,"kind":"organization","name":"Corbus Pharmaceuticals Holdings, Inc.","symbol":"CRBP"},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"ten_percent_owner":true}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":2,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"ten_percent_owner":true}},{"id":25044,"kind":"person","name":"Chen Bihua","position":3,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-02-06T21:00:46.000Z","date":"2024-02-02","kind":"purchase","planned":false,"acquired":true,"shares":750000,"price":19,"value":14250000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\") serves as General Partner of the Master Fund. Bihua Chen serves as manager of Cormorant, GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."}],"balance_after":1475000,"source":{"system":"sec-edgar","filing":"0000929638-24-000383","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583977/000092963824000383/form4.xml","form_type":"4"}},{"id":1666302,"issuer":{"id":6261,"kind":"organization","name":"Corbus Pharmaceuticals Holdings, Inc.","symbol":"CRBP"},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"ten_percent_owner":true}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":2,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"ten_percent_owner":true}},{"id":25044,"kind":"person","name":"Chen Bihua","position":3,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-01-30T21:23:10.000Z","date":"2024-01-26","kind":"purchase","planned":false,"acquired":true,"shares":3200,"price":38.49,"value":123168.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F15","text":"Represents the weighted average sale price of shares of common stock purchased in a series of open market transactions on the transaction date at prices ranging from $38.25 to $38.98 per share. The Reporting Persons undertake to provide, upon request by the staff of the SEC issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of these shares were purchased by the Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\") serves as General Partner of the Master Fund. Bihua Chen serves as manager of Cormorant, GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."}],"balance_after":725000,"source":{"system":"sec-edgar","filing":"0000929638-24-000304","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1583977/000092963824000304/form4.xml","form_type":"4"}},{"id":1666301,"issuer":{"id":6261,"kind":"organization","name":"Corbus Pharmaceuticals Holdings, Inc.","symbol":"CRBP"},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"ten_percent_owner":true}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":2,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"ten_percent_owner":true}},{"id":25044,"kind":"person","name":"Chen Bihua","position":3,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-01-30T21:23:10.000Z","date":"2024-01-26","kind":"purchase","planned":false,"acquired":true,"shares":43754,"price":37.49,"value":1640337.46,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F14","text":"Represents the weighted average sale price of shares of common stock purchased in a series of open market transactions on the transaction date at prices ranging from $37.22 to $37.99 per share. The Reporting Persons undertake to provide, upon request by the staff of the SEC issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of these shares were purchased by the Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\") serves as General Partner of the Master Fund. Bihua Chen serves as manager of Cormorant, GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."}],"balance_after":721800,"source":{"system":"sec-edgar","filing":"0000929638-24-000304","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1583977/000092963824000304/form4.xml","form_type":"4"}},{"id":1666300,"issuer":{"id":6261,"kind":"organization","name":"Corbus Pharmaceuticals Holdings, Inc.","symbol":"CRBP"},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"ten_percent_owner":true}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":2,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"ten_percent_owner":true}},{"id":25044,"kind":"person","name":"Chen Bihua","position":3,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-01-30T21:23:10.000Z","date":"2024-01-26","kind":"purchase","planned":false,"acquired":true,"shares":16484,"price":36.53,"value":602160.52,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F13","text":"Represents the weighted average sale price of shares of common stock purchased in a series of open market transactions on the transaction date at prices ranging from $36.15 to $37.02 per share. The Reporting Persons undertake to provide, upon request by the staff of the SEC issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of these shares were purchased by the Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\") serves as General Partner of the Master Fund. Bihua Chen serves as manager of Cormorant, GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."}],"balance_after":678046,"source":{"system":"sec-edgar","filing":"0000929638-24-000304","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1583977/000092963824000304/form4.xml","form_type":"4"}},{"id":1666299,"issuer":{"id":6261,"kind":"organization","name":"Corbus Pharmaceuticals Holdings, Inc.","symbol":"CRBP"},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"ten_percent_owner":true}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":2,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"ten_percent_owner":true}},{"id":25044,"kind":"person","name":"Chen Bihua","position":3,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-01-30T21:23:10.000Z","date":"2024-01-26","kind":"purchase","planned":false,"acquired":true,"shares":32295,"price":35.83,"value":1157129.85,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F12","text":"Represents the weighted average sale price of shares of common stock purchased in a series of open market transactions on the transaction date at prices ranging from $35.15 to $36.11 per share. The Reporting Persons undertake to provide, upon request by the staff of the SEC issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of these shares were purchased by the Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\") serves as General Partner of the Master Fund. Bihua Chen serves as manager of Cormorant, GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."}],"balance_after":661562,"source":{"system":"sec-edgar","filing":"0000929638-24-000304","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1583977/000092963824000304/form4.xml","form_type":"4"}},{"id":1666298,"issuer":{"id":6261,"kind":"organization","name":"Corbus Pharmaceuticals Holdings, Inc.","symbol":"CRBP"},"owners":[{"id":25045,"kind":"organization","name":"Cormorant Asset Management, LP","position":1,"cik":"0001583977","reported_name":"Cormorant Asset Management, LP","relationship":{"ten_percent_owner":true}},{"id":25046,"kind":"organization","name":"Cormorant Global Healthcare Master Fund, LP","position":2,"cik":"0001618442","reported_name":"Cormorant Global Healthcare Master Fund, LP","relationship":{"ten_percent_owner":true}},{"id":25044,"kind":"person","name":"Chen Bihua","position":3,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-01-30T21:23:10.000Z","date":"2024-01-26","kind":"purchase","planned":false,"acquired":true,"shares":31549,"price":34.62,"value":1092226.38,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F11","text":"Represents the weighted average sale price of shares of common stock purchased in a series of open market transactions on the transaction date at prices ranging from $34.17 to $35.10 per share. The Reporting Persons undertake to provide, upon request by the staff of the SEC issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of these shares were purchased by the Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Cormorant Asset Management, LP (\"Cormorant\") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the \"Master Fund\"). Cormorant Global Healthcare GP, LLC (\"GP LLC\") serves as General Partner of the Master Fund. Bihua Chen serves as manager of Cormorant, GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose."}],"balance_after":629267,"source":{"system":"sec-edgar","filing":"0000929638-24-000304","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1583977/000092963824000304/form4.xml","form_type":"4"}}],"next_cursor":"2024-01-30T21:23:10.000000Z,1666298"}